SUPPLEMENTARY MATERIAL

- Methods.
- Supplementary Table 1:
  Methodological characteristics of studies on deposition of C5b-9 in healthy and diseased human kidneys.
- Supplementary Table 2:
  Deposits of C5b-9 in healthy and diseased human kidneys.
- Supplementary Table 3:
  Deposits of C5b-9 in healthy and diseased human kidneys as detected with different antibodies.
- Supplementary Figure 1:
  Deposits of C5b-9 in healthy human kidneys as detected with different antibodies.
- Supplementary Figure 2:
  Deposits of C5b-9 in diseased human kidneys as detected with different antibodies.
- Supplementary Figure 3:
  Deposits of C5b-9 in healthy human kidneys as detected with different staining techniques.
- Supplementary Figure 4:
  Deposits of C5b-9 in diseased human kidneys as detected with different staining techniques.
- Supplementary Figure 5:
  Deposits of C5b-9 in healthy human kidneys as detected in different tissue sources.
- Supplementary Figure 6:
  Deposits of C5b-9 in diseased human kidneys as detected in different tissue sources.
METHODS

We searched for relevant literature on Medline, PubMed, Web of Science, and Google Scholar, using the search terms “C5b-9”, “C5b9”, “C5b-C9”, “membrane attack complex”, or “terminal complement complex” in combination with “kidney” or “renal”. We screened reference lists of included studies for additional relevant studies. We included 141 studies on deposition of C5b-9 in in vivo human kidney tissue. We excluded studies on in vitro kidney tissue, studies on animal kidney tissue, and studies that lacked an English abstract. The methodological characteristics of the included studies are summarized in Supplementary Table 1 below. The data reported by the included studies are listed in Supplementary Table 2 below.

We excluded small numbers of cases from our discussion that had unclear or unclassifiable kidney diseases without a definition, such as “angiitis” or “focal hyalnosis and sclerosis”, which were predominantly found in older studies. Kidney diseases that were studied only incidentally are listed at the end of Supplementary Table 1 without a discussion in the text.

We followed the classifications as used in the original studies to regard kidney tissue as healthy and to group kidney diseases. We followed the terminologies as used in the original studies to describe the localization, pattern, and intensity of staining. Glomerular staining includes staining in the mesangium and/or along the glomerular capillary wall without further specification. We followed the classification of staining as absent or present as described in the original studies. We identified the antibodies used for staining according to their clone names given in the original studies and regarded them as unknown if a clone name was not given.

We cautiously interpreted studies that used a combination of antibodies against individual components of C5b-9, such as C6 and C9, instead of a selective antibody to stain deposits of C5b-9, because of the limitations discussed in the text.

Our findings derived from the included studies are summarized in Figure 1 and Table 1. For Figure 1, we calculated the proportions of studies that reported staining of deposits of C5b-9 to be either absent or present relative to the total number of these studies, we calculated the medians of the proportions of patients reported in the studies to exhibit staining, and we calculated the medians of the staining intensities reported in the studies, all separately for different localizations of the staining and for different kidney diseases. We omitted studies that did not report the respective data from each calculation.

We omitted studies that included only one patient from the calculation of the medians of the proportions of patients reported to exhibit staining. We omitted patients exhibiting no staining from the calculation of the medians of the staining intensities. For comparability, we rescaled staining intensities that were reported on a scale from − to ++++ to the most commonly used scale from − to ++. In Table 1, we listed the histological lesions and clinical characteristics that were reported to correlate with staining of deposits of C5b-9 and are discussed in detail in the text, all separately for different localizations of the staining and for different kidney diseases.

In addition, we drew figures to illustrate how deposition of C5b-9 was related with histological lesions or clinical characteristics in various kidney diseases. We reproduced figures from their original publications or newly drew figures based on individual data reported in the original publications, as indicated in the captions of the figures. For this, we selected all available published figures and data that revealed a possible correlation between staining of C5b-9 and histological lesions or clinical characteristics.

In the text, we describe relevant correlation coefficients and other statistical measures as reported in the original studies. As two exceptions in the section on lupus nephritis, we present an odds ratio of 0.60 that we calculated with logistic regression from individual data reported in the original study and an odds ratio of 0.22 that we inverted for clarity from the ratio reported in the original study. Throughout, we indicate Pearson’s correlation coefficient as r and Spearman’s correlation coefficient as ρ. We considered p<0.05 as statistically significant, but took into account that p values might be overestimated in studies that included only small numbers of patients.
### SUPPLEMENTARY TABLE 1 | Methodological characteristics of studies on deposition of C5b-9 in healthy and diseased human kidneys

| Ref. | Year | Case description | N | Ages | Males | Tissue | Method of staining of C5b-9<sup>b</sup> | Additional staining | Correlates |
|------|------|------------------|---|------|-------|--------|--------------------------------------|---------------------|------------|
| 95   | 1981 | Unkn.            | 3 | Unkn.| Unkn. | Unkn.  | Kolb 1975                            | Igs, C1q, C3, C9    | None       |
| 44   | 1983 | Unkn.            |   | Unkn.| Fetus | Unkn.  | PolyC9-MA                            | Igs, C1q, C3, C4, C5, C6, C7, C8, C9 | None       |
| 46   | 1985 | Unkn.            |   | Unkn.| Adults| Unkn.  | Idem                                 | Idem                | None       |
| 96   | 1986 | Isolated microscopic hematuria | 6 | Adults | Unkn. | Biopsy | Anti-C5b-9(m) | Igs, C3 | None |
| 67   | 1987 | Kidney carcinoma | 2 | Adults | Unkn. | Nephrect. | Idem | Igs, C3, C5, Fn, Vn | None |
| 126  | 1987 | Traumatic death  | 3 | 0-65 | Unkn. | Autopsy or unkn. | PolyC9-MA | Igs, C3, C5 | Age |
| 127  | 1987 | Kidney calculus, kidney tumor, or kidney trauma without histological lesions | 4 | Unkn. | Unkn. | Unkn. | PolyC9-MA | Igs, C1q, C3, C4, C5, C9, P, Fn, vimentin, collagen, laminin, cytokeratin, uromodulin | None |
| 76   | 1987 | Unkn.            | 3 | Unkn.| Unkn. | Autopsy | C5 and C9 | Igs, C1q, C3, C4, Vn | None |
| 137  | 1987 | Unkn.            | 2 | Unkn.| Unkn. | Nephrect. | PolyC9-MA | IgA, C3 | Age |
| 52   | 1987 | Clinical signs of glomerulopathy without lesions on immunofluorescence microscopy | 4 | 5-37 | 75%   | Biopsy | Anti-MAC-neo | Igs, C1q, C3b/C3c, C3d, C4, C5, C6, C9, P, FB, FH, Fn, Vn | Age, sex, blood pressure, creat., proteinuria, hematuria, histological lesions |
| 97   | 1988 | Kidney calculus, kidney tumor, or kidney trauma without histological lesions | 4 | 43-66 | Unkn. | Unkn. | PolyC9-MA | Igs, C3, C4, C5, C9 | None |
| No. | Year | Diagnosis                                      | Age | Gender | Procedure | Technique | Additional Tests | Findings |
|-----|------|-----------------------------------------------|-----|--------|-----------|-----------|------------------|----------|
| 70  | 1989 | Isolated microscopic hematuria Kidney transplants without rejection | 19  | Unkn.  | Biopsy   | C6 and C9 | Indir.fr.fluor. | Igs, C1q, C3, Cn, Vn |
| 72  | 1989 | Isolated microscopic hematuria                 | 9   | Unkn.  | Idem     | Idem      | Indir.fr.fluor.  | Igs, C3, Vn |
| 77  | 1989 | No histological lesions                        | 8   | Unkn.  | Autopsy  | Unkn.     | Indir.fr.fluor.  | None        |
| 75  | 1993 | Kidney tumor or kidney trauma                  | Unkn. | Unkn. | Nephrect. | PolyC9-MA | Indir.fr.fix.fluor. | Igs, C3c, C3d, C5, C9, Vn, Vn receptor |
| 135 | 1993 | Kidney transplants or traffic accidents without lesions on light or immunofl. microscopy | 8   | Unkn.  | Unkn.    | Unkn.     | Indir.fr.fix.fluor. | Lysozyme, α1-antitrypsin, α1-antichymotrypsin |
| 110 | 1995 | Kidney donors before transplantation            | 4   | Unkn.  | Nephrect. | aE11      | Indir.fr.fix.perox. | None |
| 94  | 1995 | Unkn.                                         | 8   | Unkn.  | Unkn.    | Unkn.     | Indir.fr.fix.fluor. | None |
| 111 | 1996 | Kidney donors before transplantation or Wilms’ tumor | 7   | Unkn.  | Nephrect. | WU-7,2    | Indir.fr.fix.perox. | CR1 |
| 138 | 1996 | Renal cell carcinoma                           | 10  | Unkn.  | Unkn.    | PolyC9-MA | Indir.fr.fix.perox. | C3, CD59, DAF, MCP |
| 139 | 1997 | Early-stage renal cell carcinoma without infiltrating lymphocytes, pyelonephritis, or lesions on immunofl. microscopy | 6   | Unkn.  | Nephrect. | Unkn.     | Indir.fr.fix.perox. | Igs, C3, MCP |
| 128 | 2001 | Kidney malignancy                              | 5   | Unkn.  | Nephrect. | aE11      | Indir.fr.fix.perox. | IgA, C3, C3d, CD3, CD68, HLA-DR, αβ1-integrin, LFA1, ICAM1 |
| 112 | 2002 | Kidney donors before transplantation            | 5   | Unkn.  | Biopsy   | aE11      | Indir.fr.fix.perox. | C1q, C3c, C4d, C6, MBL, MASP1, FB |
| 129 | 2003 | Kidney donors shortly after transplantation     | 15  | Unkn.  | Biopsy   | aE11      | Indir.fr.fix.fluor. | None |
| Year | Location | Diagnosis | Age | Gender | Sample Type | Staining | Immunohistochemistry | Comments |
|------|----------|-----------|-----|--------|-------------|----------|---------------------|----------|
| 84   | 2004     | Normal kidney function without hypertension, diabetes, urinary abnormalities, or lesions on light or immunofl. microscopy | 12  | Unkn. | Autopsy     | Indir.fr.perox. | Igs, C1q, C3, C4d, Vn, CD59, CML, αSMA, ssDNA | None     |
| 83   | 2004     | Kidney transplants before reperfusion | 10  | Unkn. | Biopsy      | Indir.fr.fluor. | Igs, C1q, C3, C4, C4d, CD59 | None     |
| 113  | 2004     | Unkn.     | Unkn.| Unkn. | Biopsy      | Indir.fix.perox. | Glycated CD59 | None     |
| 114  | 2006     | Asymptomatic normocomplementemic hematuria | 7   | Children | Unkn. | Dir.fr.fix.perox. | None | None     |
| 115  | 2008     | Kidney tumor | Unkn.| Unkn. | Nephrect.   | Indir.fix.perox. | None | None     |
| 90   | 2009     | Kidney transplants without histological lesions | 5   | Unkn. | Biopsy      | Not applicable | Liquid chromatography and mass spectrometry | None     |
| 116, 117 | 2009, 2010 | Macroscopic hematuria or renal carcinoma without histological lesions on light, immunofl., or electron microscopy | 2   | Unkn. | Nephrect.   | Indir.fr.fix.fluor. | Igs, C1q, C3c, C3d, C4d, MBL, FB | None     |
| 118  | 2011     | Unkn.     | Unkn.| Unkn. | Unkn.       | Unkn.     | Igs, C3, TINag, Fas antigen, collagen, nephrocystin 1 | Not applicable |
| 103  | 2012     | Unkn.     | 6   | Unkn. | Biopsy      | Indir.fluor. | Igs, C1q, C3 | None     |
| 119  | 2013     | No kidney disease | 5   | Unkn. | Autopsy     | Indir.fr.fluor. | Igs, C1q, C3, MBL, ficolin-2 | None     |
| 120  | 2013     | Kidney cancer | 1   | Adult | 100% | Nephrect.   | Unkn.     | C3 | Not applicable |
| 121  | 2014     | Kidney carcinoma | 1   | Unkn. | Nephrect.   | Indir.fix.perox. | Igs, C1q, C3c, C3d, C4d, P, FB, fibr. | None     |
| 131  | 2015     | Pregnant women without hypertension | 25  | Unkn. | 0% | Autopsy     | Indir.fix.perox. | Igs, C1q, C3d, C4d, MBL, P, caspase 3 | None     |
| 130  | 2015     | Kidney transplants unsuitable for transplantation | 9   | Unkn. | Unkn.       | Indir.fix.perox. | C1q, C4d, MBL | None     |
| Case | Year | Diagnosis | Age | Gender | Histological Findings | Procedure | Histological Markers | Other Findings |
|------|------|-----------|-----|--------|-----------------------|-----------|---------------------|---------------|
| 122  | 2016 | Renal cancer | Adult | 100% | Nephrectomy | Fluor. | None | None |
| 123  | 2017 | Slight proteinuria or hematuria without histological lesions | 7-62 | 57% | Biopsy | Indir. fix. fluor. | MBL, LC3, p62, synaptopodin | None |
| 124  | 2017 | Suspected glomerulopathy with normal kidney function, no proteinuria, no or minimal histological lesions, and no kidney failure during ten years of follow-up | 8-56 | 47% | Biopsy | Indir. fix. perox., liquid chromatography and mass spectrometry | C1q, C3c | None |
| 92   | 2017 | Unkn. | Unkn. | Unkn. | Protocol biopsy | Liquid chromatography and mass spectrometry | Not applicable | None |
| 133  | 2018 | Incidental trauma | Unkn. | Unkn. | Biopsy | Autopsy | C1q, C3, C4d | None |
| 136  | 2018 | Normal kidney function despite sepsis or septic shock, administration of colistin or contrast, kidney transplantation, or other risk factor of acute kidney injury | 29-95 | 69% | | | FH | None |
| 27   | 2018 | No diabetes and no histological lesions | 30-97 | 61% | Autopsy | Indir. fix. perox. | C1q, C4d, MBL | None |
| 132  | 2018 | Mild hematuria, minimal change disease, focal segmental sclerosis, autopsy without kidney disease | Unkn. | Unkn. | Biopsy | | Idem | None |
| 28   | 2018 | Renal carcinoma | 37-73 | 45% | Nephrectomy | Indir. fr. perox. | C1q, FB, MBL, MASP | None |
| 31   | 2019 | Urinary tract malignancy | Unkn. | Unkn. | Nephrectomy | Indir. fluor. | KIM1 | None |
| 18   | 2019 | No histological lesions | Unkn. | Unkn. | Biopsy | Indir. fix. perox. | Igs, C3b/C3c, C3d, C9, CD68 | None |
| 134  | 2019 | Unkn. | Unkn. | Biopsy | | | Igs, C1q, C3, C4d | Not applicable |
| No. | Year | Diagnosis | Age | Gender | Race | Procedure | Method | Antibodies | Notes |
|-----|------|-----------|-----|--------|------|------------|--------|------------|-------|
| 102 | 2019 | Potential kidney donor with normal kidney function | 1 | Unkn. | Unkn. | Biopsy | aE11 | Indir.fix.perox. | Igs C1q, C3b/ C3c, C3d, C4d, P, FH, FHR1, FHR5, CD68 | Not applicable |
| 125 | 2020 | Unkn. | | | | Biopsy | Idem | Idem | Idem | None |

**Minimal change nephropathy**

| No. | Year | Diagnosis | Age | Gender | Race | Procedure | Method | Antibodies | Notes |
|-----|------|-----------|-----|--------|------|------------|--------|------------|-------|
| 96  | 1986 | Minimal change nephrotic syndrome | 5 | Adults | | | Anti-C5b-9(m) | Indir.fr.fluor. | Igs, C1q, C3b/C3c, C3d, C3g, C5, C8, C9, FH | IFTA |
| 141 | 1986 | Minimal change nephropathy | 3 | 2-14 | | Biopsy | Anti-C5b-9(m) | Indir.fr.fluor., indir.fix. fr.perox. | Igs, C1q, C3c, C4, fibr. | None |
| 67  | 1987 | Minimal change disease | 7 | Unkn. | | | | Igs, C3, C5, Fn, Vn | None |
| 98  | 1987 | Minimal change nephropathy | 3 | 2-14 | | Biopsy | Anti-C5b-9(m) | Indir.fr.fluor., indir.fix. fr.perox. | Igs, C1q, C3c, C4, fibr. | None |
| 72  | 1989 | Minimal change nephrotic syndrome | 3 | Adults | | | Anti-C5b-9(m) | Indir.fr.fluor., imm.electr. | Igs, C3, Vn | None |
| 70  | 1989 | Minimal change nephropathy | 3 | Unkn. | | Biopsy | C6 and C9 | Indir.fr.fluor. | Igs, C1q, C3, Cn, Vn | None |
| 57  | 1989 | Minimal change nephropathy | 6 | Unkn. | | Biopsy | Anti-MAC | Indir.fix.perox., dir.fr.fluor. | Igs, C1q, C3, C5, C9, fibr. | None |
| 61  | 1990 | Lipoid nephrosis | 3 | Unkn. | | Biopsy | Xia 1988 | Indir.fr.fluor. | Igs, C3c, C5, C6, C7, C8, C9, Vn | None |
| 81  | 1991 | Minimal change nephrotic syndrome | 9 | Unkn. | | Biopsy | PolyC9-MA | Indir.fr.fix.fluor. | Igs, C1q, C3, C4, CD59, CD45, fibr. | None |
| 75  | 1993 | Minimal change nephrotic syndrome | 10 | Unkn. | | Biopsy | PolyC9-MA | Indir.fr.fix.fluor. | Igs, C3c, C3d, C5, C9, Vn, Vn receptor | None |
| 79  | 1994 | Minimal change nephrotic syndrome | 2 | 18-23 | 50% | Biopsy | A239 | Indir.fr.fix.perox. imm.electr. | Vn, Vn receptor | None |
| ID  | Year | Diagnosis                  | Age     | Sex | Creatinine | Proteinuria | Hematuria | Serum IgA mRNA expression | Proteinuria Morphometry | Indirect Staining  | Other Parameters |
|-----|------|---------------------------|---------|-----|------------|-------------|-----------|---------------------------|------------------------|-------------------|-----------------|
| 139 | 1997 | Minimal change nephrotic syndrome | 100%    | Biopsy | Unkn. | Indir.fr.perox. | Igs, C3, MCP | Not applicable |
| 142 | 1999 | Minimal change nephropathy | 60%     | Open biopsy | aE11 | Indir.fr.perox. | IgA, C3, C3d | Tubular basement membrane morphometry |
| 128 | 2001 | Minimal change nephrotic syndrome | 5       | Unkn. | Unkn. | Indir.fr.fluor. | Igs, C1q, C3 | Age, sex, creat., proteinuria, hematuria, serum IgA, C3 mRNA expression |
| 143 | 2002 | Minimal change disease | 4       | Biopsy | Unkn. | Indir.fr.fluor. | Igs, C1q, C3, FHR5 | None |
| 113 | 2004 | Minimal change nephropathy | 1       | Biopsy | Unkn. | Indir.fr.perox. | Glycated CD59 | Not applicable |
| 85  | 2005 | Minimal change nephrotic syndrome | 10      | Unkn. | Unkn. | Indir.fr.perox. | Igs, C1q, C3c, C4, C4bp, MBL, MASP1, FB, CD59, fibr. | None |
| 86  | 2007 | Minimal change nephritic syndrome | 10      | Unkn. | Unkn. | Indir.fr.fluor. | Igs, C1q, C3c, C4, MBL, MASP1, FB, CD59, C4bp, fibr. | None |
| 87  | 2010 | Minimal change nephrotic syndrome | 10      | Unkn. | Unkn. | Indir.fr.fluor. | Igs, C1q, C3c, C4d, MBL, FB, CD59, C4bp | None |
| 116 | 2009 | Minimal change nephropathy | 8       | Biopsy | Unkn. | Indir.fr.fluor. | Igs, C1q, C3c, C3d, C4d, MBL, FB | None |
| 87  | 2010 | Minimal change nephritic syndrome | 10      | Unkn. | Unkn. | Indir.fr.fluor. | Igs, C1q, C3c, C3d, MBL, FB | None |
| 18  | 2019 | Minimal change nephropathy | 4       | Unkn. | Unkn. | Indir.fr.perox. | Igs, C3b/C3c, C3d, C9, CD68 | None |
| Glomerular basement membrane diseases |
|--------------------------------------|
| 96 1986  | Alport’s syndrome | 1 | Adult | Unkn. | Unkn. | Anti-C5b-9(m) | Indir.fr.fluor. | Igs, C1q, C3b/C3c, C3d, C3g, C5, C8, C9, FH |
| 139 1997  | Thin basement membrane disease | 1 | 42 | 0% | Biopsy | Unkn. | Indir.fr.fix.perox. | Igs, C3, MCP |
| 143 2002  | Thin basement membrane nephropathy | 12 | Unkn. | Unkn. | Biopsy | Unkn. | Indir.fr.fluor. | Igs, C1q, C3, FHR5 |
| 85 2005  | Thin basement membrane disease | 10 | Unkn. | Unkn. | Biopsy | Unkn. | Indir.fr.perox. | None |
| 86 2007  | Thin basement membrane disease | 10 | Unkn. | Unkn. | Biopsy | Unkn. | Indir.fr.fluor. | None |
| 87 2010  | Thin basement membrane disease | 10 | Unkn. | Unkn. | Biopsy | Unkn. | Indir.fr.fluor. | None |
| 130 2015  | Alport’s syndrome | 5 | Unkn. | Unkn. | Biopsy | A239 | Indir.fix.perox. | C1q, C4d, MBL |
| 18 2019  | Thin basement disease | 4 | Unkn. | Unkn. | Unkn. | aE11 | Indir.fix.perox. | None |

| Hypertensive nephropathy |
|--------------------------|
| 95 1981  | Benign nephrosclerosis | 2 | Unkn. | Unkn. | Unkn. | Kolb 1975 | Dir.fr.fluor. | Igs, C1q, C3, C9 |
| 44 1983  | Hypertensive nephrosclerosis | 3 | Unkn. | Unkn. | Biopsy or nephrect. | PolyC9-MA | Indir.fr.fluor. | Igs, C1q, C3, C4, C5, C6, C7, C8, C9 |
| 67 1987  | Arterionephrosclerosis | 6 | Unkn. | Unkn. | Biopsy | PolyC9-MA | Indir.fr.fluor. | Igs, C3, C5, Fni, Vn |
| 143 2002  | Hypertensive nephrosclerosis | 2 | Unkn. | Unkn. | Biopsy | Unkn. | Indir.fr.fluor. | Igs, C1q, C3, FHR5 |
| 84 2004  | Benign nephrosclerosis | 7 | 54-84 | 71% | Autopsy | Unkn. | Indir.fix.fr.perox. | Igs, C1q, C3, C4d, CD59, Vn, CML, αSMA, ssDNA |
| Hypertension without kidney involvement | 9 | 65-88 | 33% | Idem | Idem | Idem | Idem |
| 131 2015  | Pregnant women with preeclampsia | 11 | 26-40c | 0% | Autopsy | Unkn. | Indir.fix.perox. | Igs, C1q, C3d, C4d, MBL, P, caspase 3 |
| Young non-pregnant women with chronic hypertension | 14 | Unkn. | 0% | Idem | Idem | Idem | Idem |
| Case | Year | Diagnosis | Age | Gender | Symptoms | Comorbidities | Cause of Death | Comments |
|------|------|-----------|-----|--------|----------|---------------|----------------|----------|
| 44   | 1983 | Diabetes mellitus | 7   | Unkn.  | Biopsy or nephrect. | PolyC9-MA | Indir.fr.fix.fluor. | Igs, C1q, C3, C4, C5, C6, C7, C8, C9 | None |
| 67   | 1987 | Diabetic nephropathy | 2   | Adults | Anti-C5b-9(m) | Indir.fr.fluor., imm.electr. | Igs, C1q, C3b/C3c, C3d, C3g, C5, C8, C9, FH | IFTA |
| 96   | 1986 | Diabetic glomerulosclerosis | 9   | Unkn.  | Biopsy or nephrect. | PolyC9-MA | Indir.fr.fluor. | Igs, C3, C5, Fn, Vn | None |
| 70   | 1989 | Diabetic nephropathy | 3   | Unkn.  | Biopsy | C6 and C9 | Indir.fr.fluor. | Igs, C1q, C3, Cn, Vn | None |
| 72   | 1989 | Diabetic glomerulosclerosis | 3   | Adults | Anti-C5b-9(m) | Indir.fr.fluor. | Igs, C3, Vn | None |
| 139  | 1997 | Diabetic nephropathy | 2   | 41-59  | 50% | Biopsy | Unkn. | Indir.fr.fix.perox. | Igs, C3, MCP | Age, sex, hypertension, proteinuria, nephrotic syndrome |
| 142  | 1999 | Diabetic nephropathy | 3   | Unkn.  | Unkn. | Unkn. | Unkn. | Indir.fr.fluor. | Igs, C1q, C3 | Glomerulosclerosis |
| 84   | 2004 | Diabetic nephropathy after transplantation | 27  | 40-86  | 81% | Autopsy | Unkn. | Indir.fr.fix.perox. | Igs, C1q, C3, CD59, Vn, CML, αSMA, ssDNA | Diabetic glomerulosclerosis |
| 28   | 2018 | Diabetes mellitus type 2 | 62  | 27-79c | 66% | Biopsy | aE11 | Indir.fr.perox. | C1q, MBL, FB, MASP5s | Proteinuria, serum C5b-9, urine RBP and NGAL, interstitial cellular infiltration, IFTA |
| 27   | 2018 | Diabetes mellitus type 1 or 2 with diabetic nephropathy | 101 | 43-95c | 53% | Autopsy | Unkn. | Indir.fr.perox. | C1q, C4d, MBL | Diabetic nephropathy class, IFTA |

Diabetic nephropathy after transplantation
| Study No. | Year | Disease Description | Age | Gender | Sample Type | Immunoassay | Additional Notes |
|-----------|------|---------------------|-----|--------|-------------|-------------|-----------------|
| Membranous nephropathy | 44 1983 | Membranous nephropathy | 3 Unkn. | Unkn. | Biopsy | PolyC9-MA | Igs, C1q, C3, C4, C5, C6, C7, C8, C9 |
| Idiopathic membranous nephropathy I, II, III | 96 1986 | Adults | 6 Unkn. | Unkn. | Anti-C5b-9(m) | Indir.fr. | Igs, C1q, C3b/C3c, C3d, C3g, C5, C8, C9, FH |
| Medication-induced membranous nephropathy I, II, III, IV | 141 1986 | 2-14d | 2 Unkn. | Biopsy | Anti-C5b-9(m) | Indir.fr., imm.electr. | None |
| Membranous glomerulonephritis | 98 1987 | 2-14d | 2 Unkn. | Biopsy | Anti-C5b-9(m) | Indir.fr., imm.electr. | None |
| Membranous glomerulopathy | 67 1987 | Unkn. | 11 Unkn. | Biopsy | PolyC9-MA | Indir.fr. | None |
| Idiopathic membranous glomerulonephritis | 72 1989 | Adults | 7 Unkn. | Unkn. | Anti-C5b-9(m) | Indir.fr., imm.electr. | None |
| Membranous glomerulonephritis | 70 1989 | Unkn. | 9 Unkn. | Unkn. | C6 and C9 | Indir.fr. | None |
| Membranous nephropathy | 57 1989 | Unkn. | 22 Unkn. | Unkn. | Anti-MAC | Indir.fix., dir.fr. | None |
| Idiopathic membranous nephropathy | 77 1989 | Unkn. | 12 Unkn. | Unkn. | Anti-C5b-9(m) | Indir.fr. | None |
| Membranous nephropathy due to hepatitis B | 81 1991 | Unkn. | 18 Unkn. | Unkn. | PolyC9-MA | Indir.fr. | None |
| Idiopathic membranous nephropathy I/II, IV | 152 1989 | 5-15 | 2 Unkn. | Unkn. | PolyC9-MA | Indir.fix., imm.electr. | None |
| Membranous nephropathy II due to hepatitis B | 75 1993 | Unkn. | 2 Unkn. | Unkn. | PolyC9-MA | Indir.fr. | None |
| Year | Date | Disease | Age | Proteinuria | Tissue | Method | Markers | Other Observations |
|------|------|---------|-----|-------------|--------|--------|--------|-------------------|
| 79   | 1994 | Membranous nephropathy II, IV | 6   | 47-65       | Biopsy | A239   | Indir.fr.fix.perox. imm.electr. Vn, Vn receptor | None |
| 82   | 1995 | Idiopathic membranous glomerulonephritis | 5   | Unkn.       | Biopsy | C9     | Indir.fr.fix.fluor. C3b/C3c, CD59 | None |
| 139  | 1997 | Membranous nephropathy I, II | 7   | 23-70       | Biopsy | Unkn. | Indir.fr.fix.perox. Igs, C3, MCP | None |
| 142  | 1999 | Membranous nephropathy | 3   | Unkn.       | Unkn. | Unkn. | Indir.fix.fluor. Igs, C1q, C3 | Tubular basement membrane morphometry |
| 112  | 2002 | Idiopathic membranous nephropathy I, II, III, IV | 35  | 23-71       | Biopsy | aE11  | Indir.fr.fix.perox. CD3, CD68, HLA-DR, α3β1, LFA1β, ICAM1 | Creat., proteinuria, nephrotic syndr., glomerular hypercellularity, interstitial inflammation, IFTA |
| 143  | 2002 | Membranous nephropathy | 10  | Unkn.       | Biopsy | Unkn. | Indir.fr.fix.fluor. Igs, C1q, C3, FHR5 | None |
| 148  | 2004 | Idiopathic membranous nephropathy I, II, III, IV | 20  | 44-57<sup>c</sup> | Biopsy | aE11  | Indir.fr.perox. C1q, C3b/C3c, FH | None |
| 149  | 2004 | Lupus-like membranous nephropathy II with C4 deficiency | 1   | 100%        | Biopsy | Unkn. | Unkn. | Igs, C1q, C3, C4 | Not applicable |
| 80   | 2006 | Idiopathic membranous glomerulonephritis | 60  | 31-86<sup>c</sup> | Biopsy | Unkn. | Indir.fr.fix.fluor. Cn, phosphorylated PKC | None |
| 156  | 2010 | Idiopathic membranous nephropathy I, II, III | 24  | 28-75       | Biopsy | aE11  | Indir.fix.fluor. Igs, C1q, C3, aldose reductase, superoxide dismutase 2 | Blood pressure, creat., proteinuria, nephrotic syndr., mesangial hypercellularity, treatment effect |
| 87   | 2010 | Idiopathic segmental or diffuse membranous nephropathy I, II, III | 16  | 2-23        | Biopsy | Unkn. | Indir.fr.fluor. Igs, C1q, C3, C4d, MBL, FB, CD59, C4bp | None |
| 150  | 2011 | Primary membranous nephropathy I, II, III | 8   | 39-77       | Biopsy | aE11  | Indir.fr.fluor., imm.electr. Igs, C1q, C3, α-enolase, fibr. | None |
| Case | Year | Diagnosis | Age | Sex | Follow-up | Pathology | Immunological Markers | Other Clinical Findings |
|------|------|-----------|-----|-----|-----------|-----------|-----------------------|------------------------|
| 151  | 2011 | Membranous nephropathy | Unkn. | Unkn. | Unkn. | Biopsy | Unkn. | Indir.fluor. | Igs, C3c | None |
| 147  | 2012 | PLA2R-related membranous nephropathy after transplantation | 1 | 56 | 100% | Biopsy | Unkn. | Indir.fluor. | Igs, C1q, C3, MBL, PLA2R | Not applicable |
| 157  | 2014 | Membranous nephropathy due to treatment | 1 | 6 | 100% | Biopsy | Unkn. | Unkn. | Igs, C1q, C3, PLA2R | Not applicable |
| 153  | 2014 | Membranous glomerulopathy | Unkn. | Unkn. | Unkn. | Unkn. | aE11 | Indir.fix.imm.hist. | Igs, C1q, C3, C4d | None |
| 154  | 2015 | Alloimmune antenatal NEP-related membranous nephropathy | 1 | 0 | 0% | Biopsy | Unkn. | Fluor. | Igs, C1q, C3, NEP | Not applicable |
| 155  | 2016 | PLA2R-related membranous nephropathy with MBL deficiency | 1 | 25 | 100% | Biopsy | Unkn. | Unkn. | Igs, C1q, C3, C4, FB, P, PLA2R | Not applicable |
| 123  | 2017 | Idiopathic membranous nephropathy | 17 | 1-82c | 65% | Biopsy | Unkn. | Indir.fix.fluor. | MBL, LC3, p62, synaptopodin | None |
| 18   | 2019 | Idiopathic membranous nephropathy | 5 | Unkn. | Unkn. | Unkn. | aE11 | Indir.fix.perox. | Igs, C3b/C3c, C3d, C9, CD68 | None |

**IgA nephropathy and IgA vasculitis with nephritis**

| Case | Year | Diagnosis | Age | Sex | Follow-up | Pathology | Immunological Markers | Other Clinical Findings |
|------|------|-----------|-----|-----|-----------|-----------|-----------------------|------------------------|
| 44   | 1983 | IgA nephropathy | 3 | Unkn. | Unkn. | Biopsy | PolyC9-MA | Indir.fr.fix.fluor. | Igs, C1q, C3, C4, C5, C6, C7, C8, C9 | None |
| 96   | 1986 | Idiopathic IgA nephropathy | 7 | Adults | Unkn. | Unkn. | Anti-C5b-9(m) | Indir.fr.fluor. | Igs, C1q, C3b/C3c, C3d, C3g, C5, C8, C9, FH | IFTA |
|      |      | Schönlein-Henoch nephropathy | 2 | Idem | Idem | Idem | Idem | Idem | Idem | Idem |
| 137  | 1987 | Primary IgA nephropathy | 12 | Unkn. | Unkn. | Open biopsy | PolyC9-MA | Indir.fr.fix.fluor. | IgA, C3 | Age, sex, hypertension, creat., histological lesions |
| 67   | 1987 | IgA nephropathy | 11 | Unkn. | Unkn. | Biopsy | PolyC9-MA | Indir.fr.fix.fluor. | Igs, C3, C5, Fn, Vn | None |
| Year | Date     | Diagnosis                                      | Age | Gender | Blood Pressure | Proteinuria | Hematuria | Disease Duration | Proteinuria, Creat., Hematuria, Histological Lesions |
|------|----------|-----------------------------------------------|-----|--------|----------------|-------------|-----------|-----------------|---------------------------------------------------|
| 52   | 1987     | IgA mesangial glomerulonephritis              | 23  | Unkn.  |                | 6-56        | 78%       | Biopsy          | Anti-MAC-neo Indir.fr.fix.fluor., Igs, C1q, C3b/C3c, C3d, C4, C5, C6, C9, FB, P, FH, Fn, Vn, fibr. |
| 76   | 1987     | Primary IgA nephropathy                       | 2   | Unkn.  | 9-10           | 50%         | Idem      | Idem            | Idem Idem Idem Idem Idem Idem Idem Idem |
| 97   | 1988     | Primary IgA nephropathy                       | 30  | Unkn.  | Unkn.          | 4-17        | 70%       | Biopsy          | PolyC9-MA Indir.fluor., Igs, C3, C4, C5, C9 |
| 70   | 1989     | IgA nephropathy                               | 16  | Unkn.  | Unkn.          | Unkn.       | Biopsy    | C6 and C9       | Indir.fr.fluor., Igs, C1q, C3, Cn, Vn |
| 72   | 1989     | Idiopathic mesangial IgA nephropathy         | 10  | Adults | Unkn.          | Anti-C5b-9(m) | Unkn.     | Biopsy          | Indir.fr.fluor., Igs, C3, Vn |
| 57   | 1989     | IgA nephropathy                               | 75  | Unkn.  | Unkn.          | Biopsy      | Anti-MAC | Indir.fix.perox., dir.fr.fluor., Igs, C1q, C3, C5, C9, fibr. |
| 61   | 1990     | Henoch-Schönlein purpura nephritis           | 4   | Unkn.  | Unkn.          | Biopsy      | Xia 1988 | Indir.fr.fluor. | Igs, C3c, C5, C6, C7, C8, C9, Vn |
| 81   | 1991     | IgA nephropathy                               | 31  | Unkn.  | Unkn.          | Biopsy      | PolyC9-MA | Indir.fr.fix.fluor. | Igs, C1q, C3, C4, CD59, CD45, fibr. |
| 162  | 1991     | IgA nephropathy                               | 14  | Unkn.  | Unkn.          | Unkn.       | Indir.fluor. | Igs, C1q, C3, C5, C9 |
| 93   | 1991     | IgA nephropathy with C3 deficiency           | 1   | Unkn.  | 23             | 100%        | Open biopsy | PolyC9-MA    | Unkn. |
| 78   | 1992     | IgA nephropathy with C9 deficiency           | 2   | Unkn.  | 8-9            | 100%        | Biopsy     | PolyC9-MA    | Indir.fr.fluor. |

Disease progression:
- Advance stage
- Not applicable
| Case | Year | Diagnosis                  | Age | Gender | % | Biopsy | Antibodies/Markers | Urea | Creat | Proteinuria | Hematuria | Nephrotic Syndrome | Histological Lesions |
|------|------|----------------------------|-----|--------|----|--------|-------------------|------|-------|-------------|-----------|---------------------|---------------------|
| 75   | 1993 | IgA nephropathy            | 22  | Unkn.  | Unkn. | Biopsy | PolyC9-MA         | Igs, C3c, C3d, C5, C9, Vn, Vn receptor | None | None |
|      |      | Henoch-Schönlein purpura nephritis |     | Unkn.  | Unkn. | Idem   | Idem              | Idem | Idem |
| 110  | 1995 | Primary IgA nephropathy    | 20  | 19-45  | 60%   | Biopsy | aE11              | Igs, C3, CD3, CD68, HLA-DR | Age, creat., proteinuria, hematuria, interstitial inflammation, IFTA, disease progression |
|      |      |                            |     |        |       |        |                   | Igs, C3, CD3, C5, C7, C9, Cn, Vn, CD59, protease nexin | Proteinuria, nephrotic syndrome, mesangial expansion and hypercellularity | None |
| 163  | 1995 | IgA nephropathy            | 54  | Children | 61%  | Biopsy | Unkn.            | Vn | None |
| 58   | 1995 | IgA nephropathy            | 2   | Unkn.  | Unkn. | Biopsy | aE11, anti- C5b-9(m), B7 | C1q, C1r, C1s, C1 inh., C3c, C3d, C4c, C5, C7, C9, Cn, Vn, CD59, protease nexin | Age, sex, proteinuria, hematuria, nephritic syndrome |
|      |      | Henoch-Schönlein purpura   | 11  | 15-45  | 91%   | Biopsy | Unkn.            | Igs, C3, MCP | Age, sex, hematuria | None |
| 139  | 1997 | IgA nephropathy            | 120 | 7-53   | 42%   | Biopsy | Unkn.            | Igs, C1q, C3c, CD3, CD11, CD15, CD31, CD45, CD68, HLA-DR, fibr. | None |
|      |      | Henoch-Schönlein purpura   | 2   | 6-9    | 50%   | Idem   | Idem              | Idem | Idem |
| 160  | 1998 | Primary IgA nephropathy    | 45  | 15-48  | 47%   | Biopsy | aE11              | Igs, C1q, C3b/C3c, C4c, MBL, MASP1, P, fibr. | None |
| 142  | 1999 | IgA nephritis              | 8   | Unkn.  | Unkn. | Unkn.  | Unkn.            | Igs, C1q, C3 | Tubular basement membrane morphometry | None |
| 99   | 2000 | Henoch-Schönlein purpura nephritis | 10  | 9-23   | 40%   | Biopsy | aE11              | C3b/C3c, MBL, MASP1, C4bp | Age, sex, disease duration, creat., proteinuria, hematuria, serum IgA, histological lesions | None |
| Year | Year2 | Diagnosis                          | Age | Sex | Creat. | Proteinuria | Hematuria | IgA, C3, C3d | Indir. fix. | Igs, C1q, C3, C4, MBL, MASP1, FB, CD59, C4bp, fibr. | None | Proteinuria, hematuria, mesangial expansion, mesangial and endocapillary hypercellularity, crescents, caps, adhesion, glomerulosclerosis, IFTA | Creat., interstitial inflammation, disease progression |
|------|-------|-----------------------------------|-----|-----|--------|-------------|-----------|-------------|-------------|------------------------------------------------|------|-------------------------------------------------|------------------------------------------------|
| 2001 | 128   | IgA nephropathy                   | 14  |     | 43%    | Open biopsy | aE11       | Indir.fix.fr.perox. | IgA, C3, C3d | Age, sex, creat., proteinuria, hematuria, serum IgA, C3 mRNA expression |      |                                                  |                                                |
| 2002 | 143   | IgA nephropathy                   | 20  | Unkn. | Unkn.  | Biopsy     | Unkn.     | Indir.fr.fix.fluor. | Igs, C1q, C3, FHR5 |                                                  | None |                                                  |                                                |
| 2005 | 85    | Henoch-Schönlein purpura nephritis | 31  | 4-18 | Unkn.  | Biopsy     | Unkn.     | Indir.fr.perox. | Igs, C1q, C3c, C4, MBL, MASP1, FB, CD59, C4bp, fibr. | Not applicable | Proteinuria, hematuria, mesangial expansion, mesangial and endocapillary hypercellularity, crescents, caps, adhesion, glomerulosclerosis, IFTA |                                                  |
| 2008 | 115   | IgA nephropathy                   | 30  | 17-67d | 75%d  | Biopsy     | aE11       | Indir.fix.perox. | Igs, C1q, C3, C4, CD68, αSMA, α3β1-integrin, TGFβ1 |                                                  | Not applicable |                                                  |                                                |
| 2011 | 151   | IgA nephropathy with C9 deficiency | 1   | 44   | 100%   | Biopsy     | Unkn.     | Indir.fluor. | Igs, C3c |                                                  |      |                                                  |                                                |
| 2010 | 164   | IgA nephropathy with >1 g/d proteinuria but normal kidney function | 35  | 27-39c | 60%   | Biopsy     | Unkn.     | Indir.fr.perox. | Igs, C1q, C3, CR1, p27, WT1, nestin, laminin, fibr. | None |                                                  |                                                |
| 2014 | 159   | IgA nephropathy                   | 1   | 16   | 100%   | Biopsy     | Unkn.     | Unkn.       | Igs, C3 |                                                  | Not applicable |                                                  |                                                |
| 2015 | 130   | IgA nephropathy with TMA          | 1   | 32   | 100%   | Biopsy     | A239       | Indir.fix.perox. | C1q, C4d, MBL |                                                  | Not applicable |                                                  |                                                |
| 2017 | 165   | Idiopathic IgA nephropathy        | 96  | 4-66c | 65%   | Biopsy     | aE11       | Indir.fix.perox. | Igs, C1q, C3 |                                                  | None |                                                  |                                                |
| 2017 | 124   | IgA nephropathy                   | 25  | 0-63c | 80%   | Biopsy     | aE11       | Indir.fix.perox., liquid chromatography and mass spectrometry | C1q, C3c |                                                  |                                                  |                                                  |                                                |
| 2018 | 158   | IgA nephropathy                   | 36  | 18-84d | 66%d  | Biopsy     | Unkn.     | Fix.perox.  | C3b/C3c, C3d, C4d, FH, FHR1, FHR5 | Disease progression |                                                  |                                                |
| Year | Year | Diagnosis                                      | Biopsy | Indir. Fixation | C1q, C4d, MBL, FB | Age, sex, hypertension, creat., proteinuria, hematuria, nephrotic syndr., histological lesions, treatment, disease progression |
|------|------|------------------------------------------------|--------|----------------|-------------------|----------------------------------------------------------------------------------------------------------------------------------|
| 167  | 2019 | IgA nephropathy or IgA vasculitis with nephritis | 116    | Indir. fix. perox. | C1q, C4d, MBL, FB | Microangiopathy                                                                                                                    |
| 19   | 2020 | IgA nephropathy or Henoch-Schönlein purpura nephritis | 67     | Indir. fix. perox. | Igs, C1q, C3     | Age, sex, hypertension, creat., proteinuria, hematuria, nephrotic syndr., histological lesions, treatment, disease progression |
| 166  | 2020 | IgA nephropathy                                 | 132    | Indir. fix. perox. | Igs, C1q, C3     | Crescents                                                                                                                          |

**Lupus nephritis**

| Year | Year | Diagnosis                                      | Biopsy | Indir. Fixation | C1q, C3, C9 | Interstitial inflammation, IFTA | None |
|------|------|------------------------------------------------|--------|----------------|------------|---------------------------------|------|
| 95   | 1981 | SLE nephritis II, III, IV, V                  | 22     | Unkn.          | Igs, C1q, C3, C9 | Interstitial inflammation, IFTA | None |
| 44   | 1983 | SLE nephritis                                 | 3      | Unkn.          | Igs, C1q, C3 | None                            | None |
| 46   | 1985 | SLE with glomerulonephritis                   | 1      | Unkn.          | Igs, C3     | Not applicable                   |      |
| 96   | 1986 | SLE nephropathy II, IV                        | 9      | Adults         | Igs, C3, C5, Fn, Vn | None                            | None |
| 67   | 1987 | Proliferative systemic lupus nephritis         | 8      | Unkn.          | Igs, C3, C5, Fn, Vn | None                            | None |
| 72   | 1989 | SLE nephritis II, III, IV                     | 7      | Adults         | Igs, C3, C5   | None                            |      |
| 70   | 1989 | SLE nephritis                                 | 10     | Unkn.          | Igs, C1q, C3, Cn, Vn | None                            |      |
| 77   | 1989 | Lupus nephritis V                             | 8      | Unkn.          | Igs, C1q, C3, C4, Vn | Creat., proteinuria, serum C3 and C4, caps. adhesion |      |
| 152  | 1989 | SLE-associated membranous nephropathy         | 1      | Biopsy         | IgG, C3     | Not applicable                   |      |
|   | Year | Diagnosis                  | Age | %   | Procedure | Antibody | Other Tests                                                                 | Additional Details |
|---|------|----------------------------|-----|-----|-----------|----------|----------------------------------------------------------------------------|-------------------|
| 57 | 1989 | SLE                        | Unkn. | Unkn. | Biopsy    | Anti-MAC | Indir.fix.perox., dir.fr.fluor. Igs, C1q, C3, C5, C9, fibr.              | Serum C4          |
| 81 | 1991 | Diffuse lupus nephritis    | Unkn. | Unkn. | Biopsy    | PolyC9-MA| Indir.fr.fix.fluor. Igs, C1q, C3, C4, CD59, CD45, fibr.                  | None              |
| 75 | 1993 | Lupus nephritis IV         | Unkn. | Unkn. | Biopsy    | PolyC9-MA| Indir.fr.fix.fluor. Igs, C1q, C3, C7, C9, Vn, Vn receptor               | None              |
| 58 | 1995 | Lupus nephritis IV         | Unkn. | Unkn. | Biopsy    | aE11, anti-C5b-9(m), B7 | Indir.fr.fix.perox.            | None              |
| 111| 1996 | Lupus nephritis II, III, IV| Unkn. | Unkn. | Biopsy    | WU-7,2   | Indir.fr.perox. CR1 Histological lesions, histological activity index   |                   |
| 139| 1997 | Lupus nephritis III, V     | 19-30 | 50%  | Biopsy    | Unkn.    | Indir.fr.perox. Igs, C3, MCP                                            |                   |
| 142| 1999 | Lupus nephritis IV         | Unkn. | Unkn. | Unkn.     | Unkn.    | Indir.fluor. Igs, C1q, C3                                               |                   |
| 143| 2002 | Lupus nephritis            | Unkn. | Unkn. | Biopsy    | Unkn.    | Indir.fr.perox. Igs, C1q, C3, FHR5                                      |                   |
| 172| 2008 | Lupus nephritis V          | 27   | 0%   | Biopsy    | aE11     | Indir.fr.perox., imm.electr. Igs, C1q, C3, C4, vimentin                  |                   |
| 170| 2008 | Lupus nephritis II         | Unkn. | Unkn. | Biopsy    | Unkn.    | Indir.fluor. Igs, C1q, C3                                              |                   |
| 151| 2011 | SLE                        | Unkn. | Unkn. | Autopsy   | A239     | Indir.fix.perox. C1q, C4d, MBL                                          |                   |
| 174| 2013 | Lupus nephritis II, III, IV,V | 23-41 | 27%  | Biopsy    | WU-13,15 | Indir.fr.fluor. Igs, C1q, C3, MBL, ficolin-2                             |                   |
| 175| 2012 | TMA due to SLE with antiphospholipid syndrome | Unkn. | Unkn. | Biopsy    | Unkn.    | Indir.fluor. Igs, C1q, C3                                               |                   |
| 130| 2015 | SLE with TMA               | Unkn. | Unkn. | Biopsy    | Unkn.    | Indir.fluor. Igs, C1q, C3b, FBB, fibr.                                   |                   |
| 177| 2017 | Lupus nephritis II, III, IV,V | 10-56c | 16%  | Biopsy    | Unkn.    | Indir.fr.fluor. Igs, C1q, C3b, FBB, fibr.                                |                   |
| 174| 2018 | Lupus nephritis II, III, IV, V | Unkn. | Unkn. | Biopsy    | Unkn.    | Indir.fr.fluor. Igs, C1q, C3b, FBB, fibr.                                |                   |
| 133| 2018 | Active lupus nephritis     | Unkn. | Unkn. | Biopsy    | Unkn.    | Fluor. C5a Chronicity index                                              |                   |
| 133| 2018 | Active lupus nephritis     | 5-18d | 13%  | Biopsy    | Unkn.    | Fluor. None                                                              |                   |
| Year | Age | Disease | Gender | Disease Duration | Treatment | Pathological Findings | Immunological Findings | Other Findings |
|------|-----|---------|--------|-----------------|-----------|----------------------|------------------------|------------------|
| 171  | 2018| Lupus nephritis II, III, IV, V | 30 | 8-59 | Biopsy X197 | Indir. fix. perox. | Ig, C1q, C3, C4, fibr. | Age, race, SLEDAI, blood pressure, Hb, albumin, creat., proteinuria, hematuria, serum C3, C4, and anti-dsDNA, activity and chronicity indices, glomerulosclerosis, crescents, IFTA, treatment effect |
| 18   | 2019| Lupus nephritis III, IV, V | 51 | 18-71 | Biopsy aE11 | Indir. fix. perox. | Ig, C3b/C3c, C3d, C9, CD68 | |

**Membranoproliferative glomerulonephritis, C3 glomerulopathy, and postinfectious glomerulonephritis**

| Year | Disease | Age | Gender | Disease Duration | Treatment | Pathological Findings | Immunological Findings | Other Findings |
|------|---------|-----|--------|-----------------|-----------|----------------------|------------------------|------------------|
| 44   | MPGN I  | 3   | Unkn.  | Unkn.           | Biopsy    | PolyC9-MA            | Indir. fr. fix. fluor. | Ig, C1q, C3, C4, C5, C6, C7, C8, C9 |
| 183  | MPGN II | 2   | Unkn.  | 5-14            | Biopsy    | PolyC9-MA            | Indir. fr. fix. fluor. | Idem |
| 96   | MPGN I  | 9   | Adults | Unkn.           | Biopsy    | Anti-C5b-9(m)        | Indir. fr. fluor., imm. electr. | Ig, C1q, C3b/C3c, C3d, C3g, C5, C8, C9, FH |
| 141  | MPGN    | 2   | Unkn.  | 2-14d          | Biopsy    | Anti-C5b-9(m)        | Indir. fr. fix. fr. perox. | Ig, C1q, C3c, C4, C9, fibr. |
| 98   | MPGN    | 2   | Unkn.  | 2-14d          | Biopsy    | Anti-C5b-9(m)        | Indir. fr. fix. fr. perox. | Ig, C1q, C3c, C4, fibr. |
| 67   | MPGN I  | 3   | Unkn.  | Unkn.           | Biopsy    | PolyC9-MA            | Indir. fr. fix. fr. perox. | Ig, C3, C5, Fn, Vn |
| 126  | MPGN II | 3   | Unkn.  | Unkn.           | Biopsy    | PolyC9-MA            | Indir. fr. fix. fr. perox. | Ig, C3, C5 |
| 72   | MPGN I  | 5   | Adults | Unkn.           | Unkn.     | Anti-C5b-9(m)        | Indir. fr. fix. fr. perox. | Ig, C3, Vn |

**Note:** The table continues with similar entries for other cases.
| ID | Year | Diagnosis                          | Follow-up | Biopsy Site | Biopsy Specimen | Biopsy Results | Immunohistochemistry | Other Tests | Result | Comments |
|----|------|------------------------------------|-----------|-------------|----------------|----------------|----------------------|-------------|--------|----------|
| 57 | 1989 | MPGN I                             | 11        | Unkn.       | Biopsy        | Anti-MAC       | Indir. fix. perox., dir. fr. fluor. | Igs, C1q, C3, C5, C9, fibr. | Not applicable |
| 75 | 1993 | MPGN I                             | 1         | Idem        | Unkn.         | Idem           | Indir. fix. perox., dir. fr. fluor. | Igs, C3c, C3d, C5, C9, Vn, Vn receptor | Not applicable |
| 184| 1994 | Acute poststreptococcal glomerulonephritis | 5      | 3-17d       | Biopsy       | Unkn.          | Indir. fix. perox., dir. fr. fluor. | Igs, C1q, C3, P, Vn | None |
| 139| 1997 | MPGN I                             | 4         | 20-49       | Biopsy       | Unkn.          | Indir. fix. perox. | Igs, C3, MCP | Age, sex, nephrotic or nephritic syndr. |
| 143| 2002 | MPGN I                             | 1         | Unkn.       | Biopsy       | Unkn.          | Indir. fix. perox. | Igs, C1q, C3, FHR5 | Not applicable |
| 114| 2006 | MPGN I                             | 18        | Children    | Biopsy       | Unkn.          | Dir. fr. fix. perox. | None | Serum C5b-9 |
| 86 | 2007 | Acute poststreptococcal glomerulonephritis | 18     | 4-23        | Biopsy       | Unkn.          | Indir. fix. perox. | Igs, C1q, C3c, C4, MBL, MASP1, FB CD59, C4bp, fibr. | None |
| 179| 2009 | C3 glomerulonephritis             | 2         | 7-12        | Biopsy       | Unkn.          | Fix perox. | C3 | Age, sex, creat., proteinuria, hematuria, histological lesions, disease progression |
| 90 | 2009 | Dense deposit disease             | 8         | 11-49       | Biopsy       | Not applicable | Liquid chromatography and mass spectrometry | Not applicable |
|     |      | Immune complex-mediated MPGN    | 9         | Unkn.       | Unkn.         | Idem           | Idem         | None | Age, sex, creat., proteinuria, hematuria, serum C3 and C4, histological lesions, crescents |
| 180| 2011 | C3 glomerulonephritis             | 2         | 38-73       | Biopsy       | Not applicable | Idem         | Not applicable | Age, sex, edema, hypertension, creat., proteinuria, hematuria, serum C3 and C4, histological lesions |
|   | Year | Diagnosis                                      | Age | Time | Stage | Test | Method | Additional Information                                                                 |
|---|------|-----------------------------------------------|-----|------|-------|------|--------|----------------------------------------------------------------------------------------|
| 91| 2012 | C3 glomerulonephritis                         | 8   | 8-73$^d$ | 50%$^d$ | Biopsy | Not applicable | Idem | Not applicable | Age, sex, creat., proteinuria, hematuria, serum C3 and C4, histological lesions, disease progression | |
| 105| 2012 | Dense deposit disease                         | 1   | Unkn. | Unkn. | Idem | Idem | Idem | Idem | Idem | Not applicable | Not applicable | |
| 103| 2012 | Dense deposit disease                         | 2   | 20-42$^d$ | 100% | Biopsy | aE11 | Indir.fluor. | Idem | Unkn. | C3 | Not applicable | Not applicable | |
| 181| 2014 | Dense deposit disease                         | 2   | 20-42$^d$ | 100% | Idem | Idem | Idem | Idem | Idem | Histological lesions, disease progression | Idem | Age, sex, eGFR, histological lesions, disease progression | Treatment effect | |
| 106| 2015 | Rapid progressive C3 glomerulopathy           | 3   | 27-63 | 33%  | Biopsy | Unkn. | Perox. | Unkn. | Unkn. | C3 | Not applicable | Not applicable | |
| 107| 2015 | C3 glomerulopathy                             | 1   | 5     | 100% | Biopsy | Unkn. | Indir.fr.fix. | Unkn. | C3c, P, FHR5 | Not applicable | | |
| 182| 2016 | C3 glomerulopathy due to CFHRS5 mutation      | 1   | 28    | 100% | Nephrect. | Unkn. | Liquid chromatography and mass spectrometry | Idem | Idem | None | None | |
| 92 | 2017 | Dense deposit disease                         | 6   | 11-25 | 50%  | Biopsy | Not applicable | Idem | Not applicable | Disease duration, drusen, creat., proteinuria, hematuria, serum renin, C3, C3a, C5, C5a, and C5b-9, GBM thickness, eGFR, proteinuria, histological lesions, disease progression | Idem | |
| 101| 2018 | C3 glomerulonephritis                         | 6   | 16-61 | 50%  | Idem | Idem | Idem | Idem | C3c | None | None | |
| 102| 2019 | C3 glomerulopathy                             | 24  | 9-74$^d$ | 52%$^d$ | Biopsy | aE11 | Indir.fix.perox. | Idem | Igs C1q, C3b/ C3c, C3d, C4d, P, FH, FHR1, FHR5, CD68 | | |
| 108| 2019 | Recurrent C3 glomerulopathy in kidney transplant | 8   | Idem | Idem | Biopsy | Idem | Idem | Idem | Idem | | |
| 108| 2020 | Immune complex-mediated MPGN                  | 2   | 14-15 | 50%  | Biopsy | Unkn. | Indir.fr.fix.fluor. | Igs | C1q, C3c | Treatment effect | |
| Thrombotic microangiopathy                                                                 |
|-------------------------------------------------------------------------------------------|
| 75 1993 Hemolytic uremic syndr.                                                           | 1 | Unkn. | Unkn. | Biopsy | PolyC9-MA | Indir.fr.fix.fluor. | Igs, C3c, C3d, C5, C9, Vn, Vn receptor | Not applicable |
| 103 2012 aHUS                                                                            | 1 | Unkn. | Unkn. | Biopsy | aE11      | Indir.fluor.        | Igs, C1q, C3               | Not applicable |
| 190 2013 STEC-HUS                                                                        | 1 | 26    | 0%    | Biopsy | WU-13,15 | Indir.fix.perox.   | C3                         | Not applicable |
| 120 2013 Congenital TTP                                                                   | 2 | 2-4   | 0%    | Biopsy or unkn. | Unkn. | Indir.fix.perox. | C3                         | ADAMTS13 mutations |
| 153 2014 STEC-HUS                                                                        | 10 | 22-44d | 18%d  | Biopsy | aE11      | Indir.fix. imm.hist. | Igs, C1q, C3, C4d, CD3, CD44, CD61, CD68, caspase 3, Ki67, aquaporin, β-catenin, fibr. | None |
| 130 2015 aHUS                                                                            | 11 | 22-77 | 18%   | Autopsy or biopsy | A239 | Indir.fix.perox. | C1q, C4d, MBL              | Idem |
| STEC-HUS                                                                                 | 1 | 14    | 100%  | Biopsy | Idem      | Idem              | Idem                        | Idem |
| TMA after hematopoietic stem cell transplantation                                         | 6 | 18-54 | 50%   | Biopsy or biopsy | Idem | Idem              | Idem                        | Idem |
| Drug toxicity in kidney transplant                                                       | 2 | 40-47 | 0%    | Biopsy | Idem      | Idem              | Idem                        | Idem |
| Recurrent aHUS in kidney transplant                                                      | 3 | 6-37  | 67%   | Biopsy or biopsy | Idem | Idem              | Idem                        | Idem |
| 188 2015 aHUS                                                                            | 1 | 16    | 100%  | Biopsy | aE11      | Perox.            | None                        | Not applicable |
| 122 2016 STEC-HUS                                                                        | 1 | 2     | 100%  | Biopsy | Unkn.     | Fluor.            | None                        | Not applicable |
| 192 2017 Hypertension-associated TMA                                                      | 7 | 29-65 | 38%   | Biopsy | Unkn.     | Indir.fr.fluor.   | Igs, C3c, C4d               | Idem |
| Idem after transplantation                                                               | 2 | 38    | 50%   | Idem    | Idem      | Idem              | Idem                        | Idem |

Idem after transplantation: Idem after transplantation.
| ID  | Year | Diagnosis                                      | n  | Age range | Sex% | Method | Stain | Antigens/Markers                                                                 | Other Notes                                                                 |
|-----|------|-----------------------------------------------|----|-----------|------|--------|-------|--------------------------------------------------------------------------------|----------------------------------------------------------------------------|
| 132 | 2018 | Congenital TTP                                | 5  | 9-40      | 60%  | Biopsy | aE11  | Indir.fix.perox. Igs, C3, C4d, ADAMTS13                                      | Age, sex, creat., proteinuria, serum C3 and C4, ADAMTS13 mutations, glomerulosclerosis, arteriosclerosis, IFTA |
|     |      | Acquired TTP                                  | 8  | 22-66     | Unkn.| Autopsy or biopsy | Idem | Idem                        | Idem                                  | None                                                                 |
|     |      | Hypertension-associated TMA with deposition of C5b-9 on cultured endothelial cells | 10 | 23-72     | 57%  | Biopsy | Unkn. | Indir.fr.fluor. Igs, C3c | None                                                                 |
|     | 144  | 2018  | TMA treated with eculizumab                   | 6  | 22-65     | 50%  | Biopsy | aE11  | Indir.fr.fluor. Igs            | Medication, creat., serum C3 and C4, CH50, complement mutations, active or chronic TMA, treatment effect |
|     |      | TMA treated with eculizumab in kidney transplant | 7  | 32-72     | 29%  | Idem   | Idem  | Idem                        | Idem                                  | None                                                                 |
|     | 193  | 2020  | TMA and hypertensive emergency                | 15 | 17-61d    | 58%d | Biopsy | Unkn. | Indir.fr.fluor. IgM, C3c        | None                                                                 |
|     |      | ANCA-associated vasculitis                    | 139| 1997      | 0%   | Biopsy | Unkn. | Indir.fr.fix.perox. Igs, C3, MCP | Not applicable                         |
|     | 143  | 2002  | ANCA-associated granulomatosis                 | 6  | Unkn.     | Unkn.| Biopsy | Unkn. | Indir.fr.fix.fluor. Igs, C1q, C3, FHR5 | None                                                                 |
|     | 195  | 2006  | Idiopathic focal pauci-immune crescentic necrotizing glomerulonephritis | 34 | 25-80     | 50%  | Biopsy | aE11  | Indir.fr.perox. HLA-DR, TGFβ1, PCNA, αSMA, ICAM1, monocytes/macrophages | Creat.                                                                 |
|     | 196  | 2008  | Idem                                          | 34 | >15       | 50%  | Idem   | Idem  | Idem                        | Idem                                  |
|     |      | Idem                                          | 196| 2008      | 50%  | Idem   | Idem  | Idem                        | Idem                                  |
| Case | Year | Diagnosis | Age | Sex | Creatinine | Albumin | Proteinuria | C3 | C4 | C5 | C9 | FB | C3d | C4d | MBL | Igs | C1q | C3c | C3g | C9 | FH | Proteinuria | Disease progression | Others |
|------|------|-----------|-----|-----|------------|---------|-------------|----|----|----|----|----|-----|-----|-----|----|----|----|----|----|----|-----|------------------|-------------------|--------|
| 116  | 2009 | ANCA-associated vasculitis with pauci-immune crescentic necrotizing glomerulonephritis | 7   |     | 51-75      | 71%     | Biopsy Unkn. | Indir.fr.fix.perox. | Igs, C1q, C3c, C3d, C4d, MBL, FB, P | Creat., histological lesions, crescents |
| 117  | 2010 | ANCA-negative pauci-immune crescentic glomerulonephritis | 12  |     | 21-70      | 50%     | Biopsy Unkn. | Indir.fr.fix.fluor. | Igs, C1q, C3c, C3d, C4d, MBL | Age, sex, Hb, creat., proteinuria, serum C3, crescents, disease progression |
| 22   | 2013 | Active ANCA-associated glomerulonephritis | 29  |     | 28-89      | 41%     | Biopsy Unkn. | Indir.fix.perox. | Igs, C3d, FBB | Proteinuria, crescents, IFTA |
| 53   | 2015 | Renal ANCA-associated vasculitis | 25  |     | 35-95      | 63%     | Biopsy Ab55811 | Indir.fix.perox. | Igs, C3c, C4d, FBB, fibr. | Birmingham vasculitis activity score, eGFR, proteinuria, serum C5b-9, disease progression |
| 130  | 2015 | Granulomatosis with polyangiitis with TMA | 1   |     | 35         | 100%    | Biopsy A239 | Indir.fix.perox. | C1q, C4d, MBL | Not applicable |
| 194  | 2017 | ANCA-associated crescentic and/or necrotizing glomerulonephritis | 49  |     | 32-90      | 70%     | Biopsy Unkn. | Indir.fr.fluor. | Igs, C1q, C3c, C3d, C4d, MBL | Creat., proteinuria, histological class, crescents, IFTA |

**Interstitial nephritis**

| Case | Year | Diagnosis | Age | Sex | Creatinine | Albumin | Proteinuria | C3 | C4 | C5 | C9 | FB | C3d | C4d | MBL | Igs | C1q | C3c | C3g | C9 | FH | Proteinuria | Disease progression | Others |
|------|------|-----------|-----|-----|------------|---------|-------------|----|----|----|----|----|-----|-----|-----|----|----|----|----|----|----|-----|------------------|-------------------|--------|
| 96   | 1986 | Medication-induced acute tubulointerstitial nephritis | 1   | Adult | 1         |         | Biopsy Anti-C5b-9(m) | Indir.fr.fluor. | Igs, C1q, C3b/C3c, C3d, C3g, C5, C8, C9, FH | Not applicable |
| 70   | 1989 | Interstitial nephritis | 2   | Unkn. | 1         |         | Biopsy C6 and C9 | Indir.fr.fluor. | Igs, C1q, C3, Cn, Vn | None |
| 139  | 1997 | Minimal change, membranous, IgA, or diabetic nephropathy, mesangio- or membranoproliferative glomerulonephritis, lupus or interstitial nephritis, granulomato- | 46  |     | 3-70       | 61%     | Biopsy Unkn. | Indir.fr.fix.perox. | Igs, C3, MCP | Interstitial mononuclear infiltration, relative interstitial volume |
| Case | Year | Diagnosis                                                                 | Age | % | Test Procedure | Study | Recovery |
|------|------|---------------------------------------------------------------------------|-----|---|----------------|-------|----------|
| 143  | 2002 | Interstitial nephritis with polyangiitis, nail-patella syndrome, thin membrane disease, FSGS | 3   | Unkn. | Biopsy | Unkn. | Indir.fr.fix.fluor. | Igs, C1q, C3, FHR5, Igs, C3, TINag, collagen, nephro-cystin 1, Fas antigen |
| 118  | 2011 | Juvenile nephrophthisis                                                  | 16  | Unkn. | Biopsy | Unkn. | Indir.fr.fix.fluor. | Igs, C1q, C3c, C4d, MBL, ficolin |
| 199  | 2011 | IgG4-related tubulointerstitial nephritis                                | 1   | 59  | Biopsy | Unkn. | Fluor.       | Not applicable |
| 31   | 2019 | Acute tubulointerstitial nephritis                                      | 54  | 18-76 | Biopsy | aE11  | Indir.fluor. | KIM1 |

**Acute tubular necrosis**

| Case | Year | Diagnosis                                                                 | Age | % | Test Procedure | Study | Recovery |
|------|------|---------------------------------------------------------------------------|-----|---|----------------|-------|----------|
| 203  | 1993 | Hemorrhagic cystitis due to adenovirus type 11 after bone marrow transplantation | 1   | 21 | Biopsy | PolyC9-MA | Indir.fr.fluor. | Igs, C1q, C3, C4, fibr., adenovirus |
| 135  | 1993 | Minimal change, membranous, IgA, or diabetic nephropathy, lupus nephritis, diffuse mesangial proliferative glomerulonephritis, FSGS | 31  | Unkn. | Biopsy | Unkn. | Indir.fr.fix.fluor. | Lysozyme, α1-antitrypsin, α1-antichymotrypsin |
| 94   | 1995 | Idem                                                                        | 45  | Unkn. | Unkn. | Unkn. | Indir.fr.fix.fluor. | Igs, C1q, C3c, C3d, C4, C5, C6, C7, C8, C9 |
| 142  | 1999 | Idem                                                                        | 21  | Unkn. | Unkn. | Unkn. | Indir.fix.fluor. | Igs, C1q, C3 |
| 200  | 2005 | Acute tubular necrosis                                                      | 4   | 20-80 | Biopsy | C8    | Indir.fr.fix.fluor. | C3d, C4d |
| 136  | 2018 | Acute tubular necrosis due to sepsis, ischemia-reperfusion, delayed graft function, or medication | 21  | 35-93 | Autopsy | Unkn. | Indir.fix.perox. | FH |

- **Unkn.** indicates unknown
- **Indir.fr.** indicates indirect fluorescence
- **Indir.** indicates indirect
- **PolyC9-MA** indicates PolyC9 monoclonal antibody
- **C8** indicates C8
- **FH** indicates factor H
- **KIM1** indicates kidney injury molecule 1
- **Tubular atrophy or necrosis**
- **Tubular basement membrane morphometry**
|   |   |   |   |   |   |   |   |   |
|---|---|---|---|---|---|---|---|---|
| 31 | 2019 | Nephrotoxic acute tubular necrosis | 5 | 25-65 | 60% | Biopsy | aE11 | Indir.fluor. | KIM1 | None |
| 125 | 2020 | COVID19 with eGFR <90 ml/min or decline in eGFR by ≥30% | 6 | 51-86 | 67% | Autopsy | aE11 | Indir.fix.perox. | CD8, CD56, CD68, SARS-CoV-2 nucleocapsid protein | Histological lesions, IFTA |
|   |   |   |   |   |   |   |   |   |
| **Reflux nephropathy** |   |   |   |   |   |   |   |   |
| 44 | 1983 | Obstructive uropathy | 3 | Unkn. | Unkn. | Biopsy or nephrect. | PolyC9-MA | Indir.fr.fix.fluor. | Igs, C1q, C3, C4, C5, C6, C7, C8, C9 | None |
| 127 | 1987 | Vesicoureteral reflux | 8 | 8-51 | 13% | Biopsy or nephrect. | PolyC9-MA | Indir.fr.fluor. | Igs, C1q, C3, C4, C5, C9, P, Fn, vimentin, collagen, laminin, cytokeratin, uromodulin | None |
| 75 | 1993 | Reflux nephropathy | 1 | Unkn. | Unkn. | Biopsy | PolyC9-MA | Indir.fr.fix.fluor. | Igs, C3c, C3d, C5, C9, Vn, Vn receptor | Not applicable |
|   |   |   |   |   |   |   |   |   |
| **Kidney tumors** |   |   |   |   |   |   |   |   |
| 210 | 1996 | Renal cell carcinoma | 22 | 39-82 | 59% | Biopsy | Unkn. | Indir.fr.fix.perox. | Igs, C1q, C3, CD59, DAF, MCP, MHC I, MHC II, immune cells, vimentin, cytokeratin | None |
| 138 | 1996 | Renal cell carcinoma | 10 | Unkn. | Unkn. | Unkn. | PolyC9-MA | Indir.fr.fix.perox. | C3, CD59, DAF, MCP, CD45, G250, asparagus | None |
| 209 | 2000 | Renal cell carcinoma | 31 | Unkn. | Unkn. | Unkn. | PolyC9-MA | Indir.fr.fluor., indir.fr.fix.perox. | C1q, MBL, CD59, C3aR, C5R1, PTX3 | None |
| 207 | 2020 | Clear cell renal cell carcinoma | 20 | 37-81c | 57% | Nephrect. | aE11 | Indir.fr.fluor. | Igs, C1q, C3b/C3c, C3d, C9, C5, C8, C9, FH | None |
|   |   |   |   |   |   |   |   |   |
| **Kidney transplantation** |   |   |   |   |   |   |   |   |
| 96 | 1986 | Acute rejection | 2 | Adults | Unkn. | Biopsy | Anti-C5b-9(m) | Indir.fr.fluor. | Igs, C1q, C3b/C3c, C3d, C9, C5, C8, C9, FH | None |
| ID  | Year | Diagnosis                                      | Duration | Ranges | Procedure | Immunofluorescence | Other Tests                                      |
|-----|------|-----------------------------------------------|----------|--------|-----------|---------------------|-------------------------------------------------|
| 214 | 1986 | De novo membranous nephropathy                | 13       | R: 10-43 | Biopsy    | Anti-C5b-9(m)       | Igs, C1q, C3b/C3c, C3d, FH                      |
| 67  | 1987 | Acute rejection                               | 4        | Unkn.  | Biopsy    | PolyC9-MA           | Igs, C3, C5, Fn, Vn                             |
| 70  | 1989 | Rejection                                     | 14       | Unkn.  | Biopsy    | C6 and C9           | Igs, C1q, C3, Cn, Vn                            |
| 143 | 2002 | Interstitial rejection                         | 4        | Unkn.  | Biopsy    | Unkn.              | Igs, C1q, C3, FHR5                              |
| 129 | 2003 | Protocol biopsy one week after transplantation | 37       | D: 21-72 R: 20-77 | Biopsy    | aE11               | C1q, C3c, C4d, C6, MBL, MASP1, FB               |
| 83  | 2004 | Acute rejection in three months after         | 10       | D: 37-79° R: 21-44° | Biopsy    | Unkn.              | Igs, C1q, C3, C4, C4d, CD59                     |
| 104 | 2009 | Acute antibody-mediated rejection, living     | 1        | D: unkn. R: 20 | Biopsy    | aE11               | C4d                                             |
| 212 | 2012 | Acute antibody-mediated rejection with TMA    | 1        | R: 13   | Biopsy    | Unkn.              | C4d                                             |
| 211 | 2013 | After cold storage and 45 min after           | 33       | D: 17-84° R: 10-83° | Biopsy    | aE11               | None                                            |
|     |      | reperfusion, living or deceased donor         |          |        |           |                     |                                                 |
| 130 | 2015 | Rejection with TMA                            | 1        | Unkn.  | Idem      | Idem               | Idem                                            |
| 54  | 2018 | Delayed transplant function                   | 3        | R: 32-72 | Biopsy    | A239               | C1q, C4d, MBL                                   |
| 134 | 2019 | Acute or chronic antibody-mediated rejection, | 54       | R: 21-69° | Biopsy    | B7                 | Igs, C1q, C3, C4d                              |
|     |      | mostly from deceased donor                    |          |        |           |                     |                                                 |
| 213 | 2019 | Protocol or indication biopsy after ABO-      | 30       | D: 29-78° R: 27-76° | Biopsy    | Unkn.              | C1q, C3c, C4d                                  |
|     |      | incompatible transplantation                   |          |        |           |                     |                                                 |
| No. | Year | Diagnosis                                      | Cases | Age | Biopsy | First Fixation | Additional Reagents | Notes |
|-----|------|-----------------------------------------------|-------|-----|--------|----------------|---------------------|-------|
| 44  | 1983 | Amyloidosis                                    | 2     | Unkn. | Biopsy | PolyC9-MA      | Igs, C1q, C3, C4,  | None |
|     |      |                                               |       |      |        |                | C5, C6, C7, C8, C9|       |
| 96  | 1986 | Scleroderma with TMA                           | 1     | Adult | Biopsy | Anti-C5b-9(m)  | Igs, C1q, C3b/C3c,| Not applicable |
|     |      |                                               |       | Unkn. |        |                | C3d, C3g, C5, C8, C9, FH |       |
| 96  | 1986 | Amyloidosis                                    | 2     | Adults | Biopsy | Anti-C5b-9(m)  | Igs, C1q, C3b/C3c,| None |
|     |      |                                               |       |       |        |                | C3d, C3g, C5, C8, C9, FH |       |
| 96  | 1986 | Myeloma or light chain disease                | 4     | Adults | Biopsy | Anti-C5b-9(m)  | Igs, C1q, C3b/C3c,| None |
|     |      |                                               |       |       |        |                | C3d, C3g, C5, C8, C9, FH |       |
| 72  | 1989 | Amyloidosis                                    | 1     | Adult | Biopsy | PolyC9-MA      | Igs, C3, Vn        | Not applicable |
| 75  | 1993 | Oligomeganephronia                            | 1     | Unkn. | Biopsy | PolyC9-MA      | Igs, C3, C3d, C5, C9, Vn, Vn receptor | Not applicable |
| 219 | 1995 | Anti-glomerular basement membrane disease     | 1     | 70   | 0%     | Biopsy         | Igs, C1q, C3, C4, IL6, immune cells, fibr. | Not applicable |
| 220 | 2000 | Primary FSGS                                   | 13    | 14-77 | 60%    | Biopsy         | Igs, C3, ICAM1, αSMA, α3β1-integrin, TGFβ1 | Creat., treatment effect |
| 221 | 2005 | Renal sarcoidosis                              | 1     | 57   | 0%     | Biopsy         | Igs, C1q, C3, C4d, MBL, FBb | Not applicable |
| 222 | 2012 | Mixed type II cryoglobulinemia                 | 1     | 55   | 0%     | Biopsy         | Igs, C3            | Not applicable |
| 130 | 2015 | Medication-induced TMA                        | 2     | 40-47| 0%     | Biopsy         | A239               | C1q, C4d, MBL | Idem |
| 121 | 2014 | Anti-GBM disease                               | 10    | 20-66| 70%    | Biopsy         | Igs, C1q, C3c, C3d, C4d, C4d, FB, P, fibr. C1q, C3, C4d | Crescents |
| 223 | 2016 | Scleroderma renal crisis                       | 1     | 28   | 0%     | Biopsy         | Igs, C3c           | None |
| 224 | 2018 | Sickle cell disease nephropathy               | 3     | Unkn. | Unkn.  | Biopsy         | Igs, C3            | None |
| 225 | 2018 | aHUS, pauci-immune crescentic glomerulonephritis, Alport syndr. | 1 | 26 | 0% | Biopsy | Igs, C1q, C3, C4d, collagen | Not applicable |
| 226 | 2020 | Acute kidney injury due to rhabdomyolysis     | 6     | 5-88 |       | Biopsy         | Igs, C3c, C3d, C4d, C4d, FH, lamp-1, collectin-11, CD31 | None |
a Ages are given as ranges in years.
b The method of staining of C5b-9 is specified according to the antibody and immunohistochemical technique. The antibodies are indicated according to their clone names as reported in the original studies or indicated as unknown if a clone name was not given. The antibodies’ names correspond with those specified in Table 2. The immunohistochemical techniques are described as direct (dir.) or indirect (indir.), as fixed (fix.), frozen (fr.), or both, and as immunofluorescence (fluor.) or immunoperoxidase (perox.) and indicate the additional use of immunoelectron microscopy (imm.elect.).
c An estimated range is given based on a mean with standard deviation or median with interquartile range reported in the original study, calculated as the mean minus and plus two standard deviations or as the median minus two times the lower interquartile range and plus two times the higher interquartile range.
d This characteristic was reported in the original study for a larger population, in an unspecified part of which deposition of C5b-9 was studied.

Cn: clusterin; CR1: complement receptor 1; creat.: creatinine; D: donors; DAF: decay-accelerating factor; Fn: fibronectin; FSGS: focal segmental glomerulosclerosis; IFTA: interstitial fibrosis and tubular atrophy; Igs: immunoglobulins; immunofl.: immunofluorescence; MCP: membrane cofactor protein; micr.: microscopy; MPGN: membranoproliferative glomerulonephritis; nephrect.: nephrectomy; P: properdin; R: recipients; ref: reference; syndr.: syndrome; TMA: thrombotic microangiopathy; unkn.: unknown; Vn: vitronectin. Other abbreviations are explained in the article.
### SUPPLEMENTARY TABLE 2 | Deposits of C5b-9 in healthy and diseased human kidneys

| Ref. | Year | N  | Ages | Males | Tissue | Antibody       | Type, class | Staining of C5b-9<sup>b</sup> |
|------|------|----|------|-------|--------|----------------|-------------|-------------------------------|
|      |      |    |      |       |        |                |             | Glom.            | Mes. | Cap. | Tub. | Vas. |
| Healthy kidneys                         |      |    |      |       |        |                |             |                 |      |      |      |      |
| 95   | 1981 | 3  | Unkn.| Unkn.| Unkn.  | Kolb 1975    |              | o               |     |      |     |      |
| 44   | 1983 | Unkn. | Fetus | Unkn.| Unkn.  | PolyC9-MA    |              | o               | o   | o    |     |      |
|      |      | Unkn. | Adults | Unkn.| Unkn.  | PolyC9-MA    |              | o               |     |      |     |      |
| 46   | 1985 | Unkn. | Unkn.| Unkn. | Autopsy | aE11          |              | o               |     |      |     |      |
| 96   | 1986 | 6  | Adults | Unkn.| Biopsy | aC5b-9(m)   |              | o               | o   | o    |     |      |
|      |      | 2  | Adults | Unkn.| Nephrect. | aC5b-9(m) |              | o               |     |      |     |      |
| 67   | 1987 | 6  | Unkn. | Unkn.| Biopsy | PolyC9-MA   |              | o               | ±   | o    |     |      |
| 126  | 1987 | 1  | Unkn. | Unkn.| Autopsy | PolyC9-MA   |              | o               |     |      |     |      |
|      |      | 55-65 | Unkn.| Unkn.| Autopsy | PolyC9-MA   |              | o               |     |      |     |      |
|      |      |      |       |       |        |                |             |                 |     |      |     |      |
| 127  | 1987 | 4  | Unkn. | Unkn.| Unkn.  | PolyC9-MA    |              | o               |     |      |     |      |
| 76   | 1987 | 3  | Unkn. | Unkn.| Autopsy | C5 and C9    |              | o               |     |      |     |      |
| 137  | 1987 | 2  | Unkn. | Unkn.| Nephrect.| PolyC9-MA  |              | o 0%            |     | o    |     |      |
| 52   | 1987 | 4  | 5-37 | Biopsy | aMAC-neo | aE11           |              | o 0%            |     |      |     |      |
| 97   | 1988 | 4  | 43-66 | Unkn.| Unkn.  | PolyC9-MA    |              | o               |     |      |     |      |
| 70   | 1989 | 28 | Unkn. | Unkn.| Biopsy | C6 and C9    |              | o               |     |      |     |      |
| 72   | 1989 | 3  | Adults | Unkn.| Biopsy | aC5b-9(m)   |              | o               |     |      |     |      |
| 77   | 1989 | 8  | Unkn. | Unkn.| Autopsy | Unkn.        |              | o               |     |      |     |      |
| 75   | 1993 | Unkn.| Unkn.| Unkn.| Nephrect.| PolyC9-MA  |              | o               |     |      |     |      |
| 135  | 1993 | 8  | Unkn. | Unkn.| Unkn.  | Unkn.        |              | o               |     |      |     |      |
| 110  | 1995 | 4  | Unkn. | Unkn.| Nephrect.| aE11         |              | o               |     |      |     |      |
| 94   | 1995 | 8  | Unkn. | Unkn.| Unkn.  | Unkn.        |              | o               |     |      |     |      |
| 111  | 1996 | 7  | Unkn. | Unkn.| Nephrect.| WU-7,2      |              | ± 43%           |     |      |     |      |
| 138  | 1996 | 10 | Unkn.| Unkn.| Unkn.  | PolyC9-MA    |              | o               |     |      |     |      |
| 139  | 1997 | 6  | 47-75 | Unkn.| Nephrect.| Unkn.       |              | o               |     |      |     |      |
| 128  | 2001 | 5  | Unkn. | Unkn.| Nephrect.| aE11        |              | o               |     |      |     |      |
| 112  | 2002 | 5  | Unkn. | Unkn.| Biopsy | aE11        |              | o               |     |      |     |      |
| 129  | 2003 | 15 | 21-72 | Unkn.| Biopsy | aE11        |              | o               |     |      |     |      |
| 84   | 2004 | 5  | 50-88 | Autopsy | Unkn. | aE11        |              | o               |     |      |     |      |
| 83   | 2004 | 10 | Unkn. | Unkn.| Biopsy | Unkn.       |              | o 70%           |     |      |     |      |
| 113  | 2004 | Unkn.| Unkn.| Unkn.| Biopsy | Unkn.       |              | o 100%         |     |      |     |      |
| Case | Year | Age | Gender | Status | Methodology | Findings |
|------|------|-----|--------|--------|-------------|----------|
| 114  | 2006 | 7   | Unkn.  | Unkn.  | 1B4         | 0%       |
| 115  | 2008 | Unkn.| Unkn.  | Unkn.  | aE11        | 0%       |
| 116,117 | 2009, 2010 | Unkn. | Unkn.  | Unkn.  | Nephrect.   | 0%       |
| 118  | 2011 | 1   | Unkn.  | Unkn.  | Unkn.       |          |
| 103  | 2012 | 6   | Unkn.  | Unkn.  | Biopsy      | +/+      |
| 119  | 2013 | 5   | Unkn.  | Unkn.  | Autopsy     | WU-13,15 |
| 120  | 2013 | 1   | Adult  | 100%   | Nephrect.   |          |
| 121  | 2014 | 1   | Unkn.  | Unkn.  | Nephrect.   | Unkn.    |
| 130  | 2015 | 9   | Unkn.  | Unkn.  | A239        |          |
| 122  | 2016 | 1   | Adult  | 100%   | Nephrect.   | Unkn.    |
| 123  | 2017 | 14  | 7-62c  | 57%    | Biopsy      | Unkn.    |
| 124  | 2017 | 15  | 8-56c  | 47%    | Biopsy      | Unkn.    |
| 133  | 2018 | 3   | Unkn.  | Unkn.  | Unkn.       |          |
| 136  | 2018 | 74  | 29-95c | 69%    | Autopsy     | Unkn.    |
| 27   | 2018 | 41  | 30-97c | 61%    | Autopsy     | Unkn.    |
| 132  | 2018 | 12  | 23-83c | Unkn.  | Autopsy     | aE11     |
| 28   | 2018 | 11  | 37-73c | 45%    | Nephrect.   | aE11     |
| 31   | 2019 | Unkn.| Unkn.  | Unkn.  | Nephrect.   | aE11     |
| 18   | 2019 | 6   | Unkn.  | Unkn.  | aE11        | 17%      |
| 134  | 2019 | 1   | Unkn.  | Unkn.  | Biopsy      | B7       |
| 102  | 2019 | 1   | Unkn.  | Unkn.  | Biopsy      | aE11     |
| 125  | 2020 | Unkn.| Unkn.  | Unkn.  | aE11        |          |
### Minimal change nephropathy

| Year | Year | Age | Gender | Diagnosis | Procedure | C5b-9(m) | ± | C5b-9(m) | ± |
|------|------|-----|--------|-----------|-----------|----------|---|----------|---|
| 96   | 1986 | 5   | Adults | Unkn.    | Unkn.     | αC5b-9(m)| ○ | ○        | ○ |
| 141  | 1986 | 3   |        | 2-14d    | Unkn.     | αC5b-9(m)| ○ | ○        | ○ |
| 67   | 1987 | 7   | Unkn.  | Unkn.    | Biopsy    | PolyC9-MA| ± | ○        | + |
| 98   | 1987 | 3   |        | 2-14d    | Unkn.     | αC5b-9(m)| ○ | ○        | ○ |
| 72   | 1989 | 3   | Adults | Unkn.    | Unkn.     | αC5b-9(m)| ○ | ○        | ○ |
| 70   | 1989 | 3   | Unkn.  | Unkn.    | Biopsy    | C6 and C9| ○ | ○        | ● |
| 57   | 1989 | 6   | Unkn.  | Unkn.    | Biopsy    | αMAC     | ○ | ○        | ● |
| 61   | 1990 | 3   | Unkn.  | Unkn.    | Biopsy    | Xia 1988 | ○ | 0%       | ○ |
| 81   | 1991 | 9   | Unkn.  | Unkn.    | Biopsy    | PolyC9-MA| ● | ○        | ● |
| 75   | 1993 | 10  | Unkn.  | Unkn.    | Biopsy    | PolyC9-MA| ● | ○        | ● |
| 79   | 1994 | 2   | 18-23  | Biopsy   | A239      | ●         | + | ○        | ● |
| 139  | 1997 | 1   | 15     | Biopsy   | Unkn.     | ○         |   |          |   |
| 142  | 1999 | 5   | Unkn.  | Unkn.    | Unkn.     | αE11     | ● | 100%     |   |
| 128  | 2001 | 5   | 15-34  | Biopsy   | aE11      | ●         |   | 100%     |   |
| 143  | 2002 | 4   | Unkn.  | Unkn.    | Biopsy    | Unkn.    | ○ | 0%       |   |
| 113  | 2004 | 1   | Unkn.  | Unkn.    | Biopsy    | Unkn.    | ○ |          |   |
| 85   | 2005 | 10  | Unkn.  | Unkn.    | Unkn.     | ○         |   |          |   |
| 86   | 2007 | 10  | Unkn.  | Unkn.    | Unkn.     | ○         |   |          |   |
| 87   | 2010 | 10  | Unkn.  | Unkn.    | Unkn.     | ○         |   |          |   |
| 116, | 2009 | 8   | Unkn.  | Unkn.    | Biopsy    | Unkn.    | ● | 25%      | ++|
| 117  | 2010 |    |        |          |           | ○         |   |          |   |
| 121  | 2014 | 5   | Unkn.  | Unkn.    | Biopsy    | Unkn.    | ○ |          |   |
| 18   | 2019 | 4   | Unkn.  | Unkn.    | Biopsy    | aE11     | ● | 100%     |   |

### Glomerular basement membrane diseases

| Year | Year | Age | Gender | Diagnosis | Procedure | C5b-9(m) | ± | C5b-9(m) | ± |
|------|------|-----|--------|-----------|-----------|----------|---|----------|---|
| 96   | 1986 | 1   | Adult  | Unkn.    | Unkn.     | αC5b-9(m)| ● | ○        | ○ |
| 139  | 1997 | 1   | 42     | Biopsy   | Unkn.     | ●         |   | +        |   |
| 143  | 2002 | 12  | Unkn.  | Biopsy   | Unkn.     | ○         | ○ |          |   |
| 85   | 2005 | 10  | Unkn.  | Unkn.    | Biopsy    | Unkn.    | ○ |          |   |
| 86   | 2007 | 10  | Unkn.  | Unkn.    | Unkn.     | ○         |   |          |   |
| 87   | 2010 | 10  | Unkn.  | Unkn.    | Biopsy    | Unkn.    | ○ |          |   |
| 130  | 2015 | 5   | Unkn.  | Unkn.    | Biopsy    | A239     | 0%|          |   |
| 18   | 2019 | 4   | Unkn.  | Unkn.    | aE11      | ●         |   | 100%     |   |
### Hypertensive nephropathy

| Year | Age | Gender | Symptoms | Research Method | C5b-9 Activity |
|------|-----|--------|----------|----------------|----------------|
| 95   | 1981| 2      | Unkn.    | Unkn.          | Unkn.          |
| 44   | 1983| 3      | Unkn.    | Unkn.          | Biopsy or nephrect. |
| 67   | 1987| 6      | Unkn.    | Biopsy        | PolyC9-MA      |
| 143  | 2002| 2      | Unkn.    | Biopsy        | PolyC9-MA      |
| 84   | 2004| 7      | 54-84    | Autopsy       | Unkn.          |
| 9    | 65-88| 33% Autopsy | Unkn.    | C6 and C9     |
| 131  | 2015| 11     | 26-40c   | Autopsy       | Unkn.          |
| 14   | Unkn.| 0% | Autopsy  | Unkn.         |                |

### Diabetic nephropathy

| Year | Age | Gender | Symptoms | Research Method | C5b-9 Activity |
|------|-----|--------|----------|----------------|----------------|
| 44   | 1983| 7      | Unkn.    | Biopsy or nephrect. | PolyC9-MA |
| 96   | 1986| 2      | Adults   | Unkn.          | Unkn.          |
| 67   | 1987| 9      | Unkn.    | Biopsy        | PolyC9-MA      |
| 126  | 1987| 12     | Unkn.    | Biopsy or nephrect. | PolyC9-MA |
| 70   | 1989| 3      | Unkn.    | Biopsy        | C6 and C9     |
| 72   | 1989| 3      | Adults   | Unkn.          | αC5b-9(m)     |
| 139  | 1997| 2      | 41-59    | Biopsy        | Unkn.          |
| 142  | 1999| 3      | Unkn.    | Unkn.          | Unkn.          |
| 143  | 2002| 2      | Unkn.    | Biopsy        | Unkn.          |
| 113  | 2004| 13     | 45-77    | Biopsy        | Unkn.          |
| 84   | 2004| 27     | 40-86    | Autopsy       | Unkn.          |
| 28   | 2018| 62     | 27-79c   | Biopsy        | aE11           |
| 27   | 2018| 101    | 43-95c   | Autopsy       | Unkn.          |
| 12   | Unkn.| 59% | Autopsy  | Unkn.         |                |
| N  | Year | Adults | Unkn. | Biopsy Type | Pathological Findings | Comments |
|----|------|--------|-------|-------------|-----------------------|----------|
| 44 | 1983 | 3      | Unkn. | Biopsy     | PolyC9-MA             |          |
| 96 | 1986 | 6      | Adults| Unkn.      | αC5b-9(m) Idio.       | 0%       |
|    |      |        |       |             |                       | 100%     |
| 9  | 1986 | 2      | 2-14d| Unkn.      | αC5b-9(m) Sec.        | 78%1     |
|    |      |        |       |             |                       | 22%1     |
| 141| 1986 | 2      | Adults| Unkn.      | αC5b-9(m)             | 100%     |
| 98 | 1987 | 2      | 2-14d| Unkn.      | αC5b-9(m)             | 100%     |
| 67 | 1987 | 11     | Unkn. | Unkn.      | PolyC9-MA             | ++       |
|    |      |        |       |             |                       | +++      |
| 72 | 1989 | 7      | Adults| Unkn.      | C6 and C9             | 50%      |
|    |      |        |       |             |                       | ++       |
| 70 | 1989 | 9      | Unkn. | Unkn.      | PolyC9-MA             | 50%      |
|    |      |        |       |             |                       | ++       |
| 57 | 1989 | 22     | Unkn. | Unkn.      | aMAC                  | 50%      |
|    |      |        |       |             |                       | ++       |
| 77 | 1989 | 12     | Unkn. | Unkn.      | αC5b-9(m)             | 100%     |
|    |      |        |       |             |                       |           |
| 75 | 1993 | 2      | Unkn. | Unkn.      | PolyC9-MA             | 100%     |
| 79 | 1994 | 6      | 47-65 | 33%        | Biopsy A239           | 23%      |
|    |      |        |       |             |                       | 100%     |
| 82 | 1995 | 5      | Unkn. | Unkn.      | C9                    | 13%1     |
|    |      |        |       |             |                       | 83%1     |
| 139| 1997 | 7      | 23-70 | 29%        | Biopsy Unkn.          | 100%     |
|    |      |        |       |             |                       | ++       |
| 142| 1999 | 3      | Unkn. | Unkn.      | Unkn.                 | 100%     |
| 112| 2002 | 35     | 23-71 | 66%        | Biopsy aE11           | 100%     |
|    |      |        |       |             |                       | 100%     |
| 143| 2002 | 10     | Unkn. | Unkn.      | aE11                  | 100%     |
| 148| 2004 | 20     | 44-57c| 70%        | Biopsy aE11           | 100%     |
| 149| 2004 | 1      | Unkn. | 100%       | Biopsy aE11           |           |
| 80 | 2006 | 60     | 31-86c| 63%        | Biopsy Unkn.          | 100%     |
| 156| 2010 | 24     | 28-75 | 67%        | Biopsy aE11           | 100%     |
| 87 | 2010 | 16     | 2-23  | 100%       | Biopsy aE11           | 100%     |
| 150| 2011 | 8      | 39-77 | 38%        | Biopsy aE11           | 100%     |
| 151| 2011 | 1      | 0     | 0%         | Biopsy aE11           | 100%     |
| 147| 2012 | 1      | 56    | 100%       | Biopsy aE11           | 100%     |
| 157| 2014 | 1      | 6     | 100%       | Biopsy aE11           | 100%     |
| 153| 2014 | 1      | Unkn. | Unkn.      | aE11                  | 100%     |
| 154| 2015 | 1      | 0     | 0%         | Biopsy aE11           | 100%     |
| 155| 2016 | 1      | 25    | 100%       | Biopsy aE11           | 100%     |
| 123| 2017 | 17     | 1-82c| 65%        | Biopsy aE11           | 100%     |
| 18 | 2019 | 5      | Unkn. | Unkn.      | aE11                  | 100%     |

*PolyC9-MA* indicates polyC9-mediated attack; *αC5b-9(m)* indicates αC5b-9-mediated attack; *Sec.* indicates secondary attack; *A239* indicates A239-mediated attack; *aE11* indicates aE11-mediated attack.
### IgA nephropathy and IgA vasculitis with nephritis

| Year | Age | Gender | Tissue | Polyc9-MA | αC5b-9(m) | C5 and C9 | αMAC | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(m) | αC5b-9(}
| Year | Case | Age | Sex | Type | Autoantibody | Organ | Diagnosis | TMA | MA | Other | Notes |
|------|------|-----|-----|------|-------------|-------|-----------|-----|----|--------|-------|
| 124  | 2017 | 25  | 0-63 | 80%  | Biopsy     | aE11  | Neph.     | ●   |    |        | 100% + |
| 158  | 2018 | 36  | 18-84 | 66%  | Biopsy     | Unkn. | Neph.     | ●   |    |        | 67% +/+ |
| 167  | 2019 | 116 | 0-84 | 69%  | Biopsy     | A239  | Both      | ●   | 15%|        | 50%               |
| 19   | 2020 | 67  | 3-17 | 61%  | Biopsy     | Unkn. | Both      | ●   | 81%|        | 82%               |
| 166  | 2020 | 132 | 17-82| 54%  | Biopsy     | Unkn. | Neph.     | ●   |    |        | +/+               |

**Lupus nephritis**

| Year | Case | Age | Sex | Type | Autoantibody | Organ | Diagnosis | TMA | MA | Other | Notes |
|------|------|-----|-----|------|-------------|-------|-----------|-----|----|--------|-------|
| 95   | 1981 | 2   | Unkn.| Autopsy or biopsy | Kolb 1975 | II    | ● 100%     | 100%|    |        | 100% + |
| 7    | Unkn.| Adult | Autoantibody | Kolb 1975 | III   | ● 86%      | +   | 86%|        | 100% +/+ |
| 10   | Unkn.| Adults | Autoantibody | Kolb 1975 | IV    | ● 100%     | ++  | 100%| ++     | 100% ++ |
| 3    | Unkn.| Unkn. | Autoantibody | Kolb 1975 | V     | ○ 0%       | ● 67%|    |        | 100% ++ |
| 44   | 1983 | 3   | Unkn.| Unkn. | Biopsy     | PolyC9-MA | ●   |    |        |       |
| 46   | 1985 | 1   | 18   | 0%   | Unkn.      | aE11   | ●         |    |    |        |       |
| 96   | 1986 | 8   | Adults | Biopsy | aC5b-9(m) | II    | ● +        | ○   |    |        |       |
| 8    | Unkn.| Adults | Biopsy | aC5b-9(m) | IV    | ● 100%     | ++  | 88%| ++     |       |
| 67   | 1987 | 8   | Unkn.| Unkn. | Biopsy     | PolyC9-MA | III, IV | ● ++| ○     | ++     | +/+               |
| 72   | 1989 | 7   | Adults | Unkn. | aC5b-9(m) | II-IV  | ● 100%     |    |    |        |       |
| 70   | 1989 | 10  | Unkn.| Unkn. | Biopsy     | C6 and C9 | ●   |    |        |       |
| 77   | 1989 | 8   | Unkn.| Unkn. | Biopsy     | Unkn.  | V         | ○   | 0% | 75%    | +/+               |
| 152  | 1989 | 1   | 18   | 0%   | Biopsy     | PolyC9-MA | V     | ●         |    |    |        |       |
| 57   | 1989 | 20  | Unkn.| Unkn. | Biopsy     | aMAC   | ● 79%     |    |    |        |       |
| 81   | 1991 | 9   | Unkn.| Unkn. | Biopsy     | PolyC9-MA | IV    | ●         |    |    |        |       |
| 75   | 1993 | 4   | Unkn.| Unkn. | Biopsy     | PolyC9-MA | IV    | ●         |    |    |        |       |
| 58   | 1995 | 2   | Unkn.| Unkn. | Biopsy     | aE11, B7, αC5b-9(m) | □   |    |        |       |
| 111  | 1996 | 5   | Unkn.| Unkn. | Biopsy     | WU-7,2 | II      | +/+ | 100%| ○ 0% |       |
| 139  | 1997 | 2   | 19-30| 50%  | Biopsy     | Unkn.  | III, V   | ● 100%|    |        | +/+               |
| 142  | 1998 | 5   | Unkn.| Unkn. | Unkn.     | Unkn.  | IV       | ● 100%|    |        |       |
| 143  | 2002 | 7   | Unkn.| Unkn. | Biopsy     | Unkn.  | ● 86%    |    |    |        |       |
| 172  | 2008 | 1   | 27   | 0%   | Biopsy     | aE11   | V        | ●   |    |        |       |
|   |   |   |   |   |   |   |   |   |   |   |
|---|---|---|---|---|---|---|---|---|---|---|
| 170 | 2008 | 1 | 30 | 0% | Biopsy | Unkn. | II |   |   |   |
| 151 | 2011 | Unkn. | Unkn. | Unkn. | Biopsy | Unkn. |            |   |   |   |
| 175 | 2012 | 1 | 27 | 0% | Biopsy | Unkn. | TMA |   |   |   |
| 119 | 2013 | 11 | 23-41 | 27% | Biopsy | WU-13,15 | II-V |   |   |   |
|     |     | 2 | 23-41 | 27% | Biopsy | WU-13,15 | II | 100% |   |   |
|     |     | 3 | 23-41 | 27% | Biopsy | WU-13,15 | III | 100% |   |   |
|     |     | 3 | 23-41 | 27% | Biopsy | WU-13,15 | IV | 100% |   |   |
|     |     | 3 | 23-41 | 27% | Biopsy | WU-13,15 | V | 100% |   |   |
| 130 | 2015 | 8 | 17-49 | 0% | Autopsy | A239 | TMA | 60% |   |   |
|   |   |   |   |   |   |   |   |   |   |   |
| 173 | 2017 | 222 | 10-56 | 16% | Biopsy | Unkn. | II-VI |   |   |   |
| 174 | 2018 | 38 | Unkn. | Unkn. | Biopsy | Unkn. | II-V |   |   |   |
| 133 | 2018 | 5 | 5-18 | 13% | Biopsy | Unkn. | III | 100% |   |   |
| 171 | 2018 | 30 | 8-59 | 20% | Biopsy | X197 | II-V |   |   |   |
|     |     | 2 | 8-59 | 20% | Biopsy | X197 | II | 0% |   |   |
|     |     | 5 | 8-59 | 20% | Biopsy | X197 | III | 20% |   |   |
|     |     | 8 | 8-59 | 20% | Biopsy | X197 | IV | 50% |   |   |
|     |     | 5 | 8-59 | 20% | Biopsy | X197 | V | 60% |   |   |
|     |     | 8 | 8-59 | 20% | Biopsy | X197 | III+V | 50% |   |   |
|   |   |   |   |   |   |   |   |   |   |   |
| 18 | 2019 | 20 | 20-64 | 20% | Biopsy | aE11 | III |   |   |   |
|     |     | 22 | 21-61 | 13% | Biopsy | aE11 | IV | 87% |   |   |
|     |     | 13 | 18-71 | 23% | Biopsy | aE11 | V | 46% |   |   |

Membranoproliferative glomerulonephritis, C3 glomerulopathy, and postinfectious glomerulonephritis

|   |   |   |   |   |   |   |   |   |   |   |
|---|---|---|---|---|---|---|---|---|---|---|
| 44 | 1983 | 3 | Unkn. | Unkn. | Biopsy | PolyC9-MA | I |   |   |   |
| 2  | Unkn. | Unkn. | Nephrect. | PolyC9-MA | II |   |   |   |   |
| 183 | 1984 | 11 | 5-14 | 45% | Biopsy | PolyC9-MA | Pinf. | 86% |   |   |
|     |     |     |     |     |     |     |     | 86% |   |   |
| 96 | 1986 | 9 | Adults | Unkn. | Biopsy | αC5b-9(m) | I | 89% |   |   |
|     |     |     |     |     |     |     |     | 100% |   |   |
| 141 | 1986 | 2 | 2-14 | 2% | Unkn. | Biopsy | αC5b-9(m) | 0% |   |   |
|     |     |     |     |     |     |     |     | 50% |   |   |
|     |     |     |     |     |     |     |     | 50% |   |   |
| 98 | 1987 | 2 | 2-14 | 2% | Unkn. | Biopsy | αC5b-9(m) |   |   |   |
| 67 | 1987 | 3 | Unkn. | Unkn. | Biopsy | PolyC9-MA | I |   |   |   |
|     |     | 4 | Unkn. | Unkn. | Biopsy | PolyC9-MA | Pinf. | 4% |   |   |
|     |     | 126 | 1987 | 3 | Unkn. | Unkn. | Biopsy | PolyC9-MA | II |   |   |
|     |     | 72 | 1989 | 5 | Adults | Unkn. | αC5b-9(m) | I | 100% |   |   |
| 57 | 1989 | 11 | Unkn. | Unkn. | Biopsy | αMAC | I |   |   |   |
|     |     | 1 | Unkn. | Unkn. | Biopsy | αMAC | II |   |   |   |
| Series | Year | Age | Sex | Type | Diagnosis | Pathology | Follow-Up | Outcome |
|--------|------|-----|-----|------|-----------|-----------|-----------|---------|
| 75     | 1993 | 1   | Unkn. | Biopsy | PolyC9-MA I | ● | ● | ● |
| 2      | Unkn. | Biopsy | PolyC9-MA II | ● | ● | ● | ● |
| 1      | Unkn. | Biopsy | PolyC9-MA III | ● | ● | ● | ● |
| 184    | 1994 | 5   | 3-17d | Biopsy | Unkn. | Pinf. | ● | 80%f | 100%f |
| 139    | 1997 | 4   | 20-49 | Biopsy | Unkn. | I | 100% +/++ |
| 143    | 2002 | 2   | Unkn. | Unkn. | Biopsy | Unkn. | ● | ● |
| 114    | 2006 | 18  | Children | Biopsy | 1B4 | I | 94% +/++ |
| 86     | 2007 | 18  | 4-23 | Unkn. | Biopsy | Unkn. | Pinf. | 100%f | 100%f |
| 179    | 2009 | 2   | 7-12 | 0% | Biopsy | Unkn. | C3GN | 100% | 100% |
| 105    | 2012 | 1   | 17   | Unkn. | Biopsy | Unkn. | DDD | ● |
| 103    | 2012 | 2   | 20-42d | 100% | Biopsy | aE11 | C3GN | 100% +++ | 100% +++ | 100% +++ | 100% +++ |
| 181    | 2014 | 3   | 8-28 | 33% | Biopsy | Unkn. | DDD | ● | 67% |
| 106    | 2015 | 3   | 27-63 | 33% | Biopsy | Unkn. | C3G | 100% +++ |
| 107    | 2015 | 1   | 5    | 100% | Biopsy | Unkn. | C3GN | ● | ● |
| 182    | 2016 | 1   | 28   | 100% | Nephrect. | Unkn. | C3G | ● |
| 101    | 2018 | 3   | 7-12 | 0% | Biopsy | Unkn. | DDD | ● | ++ |
| 102    | 2019 | 24  | 9-74d | 52% | Biopsy | aE11 | C3G | 100% +/++ |
| 108    | 2020 | 2   | 14-15 | 50% | Biopsy | Unkn. | IC | 100% |

**Thrombotic microangiopathy**

| Series | Year | Age | Sex | Type | Diagnosis | Pathology | Follow-Up | Outcome |
|--------|------|-----|-----|------|-----------|-----------|-----------|---------|
| 103    | 2012 | 1   | Unkn. | Unkn. | Biopsy | aE11 | aHUS | ● | +++ | +++ | +++ | +++ |
| 190    | 2013 | 1   | 26   | 0% | Biopsy | WU-13,15 | STEC | ● |
| 120    | 2013 | 2   | 2-4  | 0% | Biopsy or unkn. | Unkn. | TTP | ● | ● |
| 153    | 2014 | 10  | 22-44d | 18% | Biopsy | aE11 | STEC | ○ |
| 130    | 2015 | 11  | 22-77 | 18% | Autopsy or biopsy | A239 | aHUS | ● |
| 1      | 14   | 100% | Biopsy | A239 | STEC | ○ | ● |
| 6      | 18-54 | 50% | Autopsy or biopsy | A239 | ● | ● |
| 3      | 6-37 | 67% | Biopsy or nephrect. | A239 | aHUS | ● |
| 188    | 2015 | 1   | 16   | 100% | Biopsy | aE11 | aHUS | ● | ● | ● |
|   | Year | Age | % | Test | Diagnosis                 | HLA | ANCA | Anti-GBM | Anti-GPI | Anti-PLA2R | Anti-ASMA | Anti-SSA | Anti-SSB | Anti-Ro/SSA | Anti-La/SSB | Anti-MOG | Anti-NKCA | Anti-TO20 | Anti-TO22 | Anti-TO21 |
|---|------|-----|---|------|---------------------------|-----|------|----------|----------|------------|-----------|----------|----------|-------------|-------------|----------|-----------|----------|----------|----------|
| 122 | 2016 | 1   | 2 | 100% | Biopsy                    | Unkn. | STEC | ●        | ●        | ●          | ●         | ●        | ●        | ●           | ●           | ●        | ●         | ●        | ●        | ●        |
| 192 | 2017 | 7   | 29-65 | 38% | Biopsy                    | Unkn. | Hypt. | ●        | 100% +   | ●          | 100% +++  | ●        | ●        | ●        | ●           | ●           | ●        | ●         | ●        | ●        | ●        |
| 2   | 2017 | 38  | 50% | Biopsy | Unkn. | Hypt. | ●        | 100% +   | ●          | 100% +    | ●        | ●        | ●        | ●           | ●           | ●        | ●         | ●        | ●        | ●        |
| 132 | 2018 | 5   | 9-40 | 60% | Biopsy                    | aE11  | TTP  | ○ 0%     | 40%       | ●          | 60%       | ●        | ●        | ●        | ●           | ●           | ●        | ●         | ●        | ●        | ●        |
| 144 | 2018 | 10  | 23-72 | 57% | Biopsy                    | Unkn. | Hypt. | ●        | ●        | ●          | ●         | ●        | ●        | ●           | ●           | ●        | ●         | ●        | ●        | ●        |
| 100 | 2019 | 6   | 22-65 | 50% | Biopsy                    | aE11  | ●    | ●        | ●        | 100% ++   | 33% +/-   | ●          | ●        | ●        | ●           | ●           | ●        | ●         | ●        | ●        | ●        |
| 7   | 2019 | 32-72 | 29% | Biopsy | aE11  | ●    | ●        | ●        | 100% +/-  | 14% ++    | ●          | ●        | ●        | ●           | ●           | ●        | ●         | ●        | ●        | ●        |
| 193 | 2020 | 15  | 17-61<sup>cd</sup> | 58%<sup>d</sup> | Biopsy | Unkn. | Hypt. | ●        | 47%       | ●          | ●         | ●        | ●        | ●           | ●           | ●        | ●         | ●        | ●        | ●        |

**ANCA-associated vasculitis**

|   | Year | Age | % | Test | Diagnosis             | HLA | ANCA | Anti-GBM | Anti-GPI | Anti-PLA2R | Anti-ASMA | Anti-SSA | Anti-SSB | Anti-Ro/SSA | Anti-La/SSB | Anti-MOG | Anti-NKCA | Anti-TO20 | Anti-TO22 | Anti-TO21 |
|---|------|-----|---|------|-----------------------|-----|------|----------|----------|------------|-----------|----------|----------|-------------|-------------|----------|-----------|----------|----------|----------|
| 139 | 1997 | 1   | 44 | 0%  | Biopsy                | Unkn. | ●    | ●        | ●        | ●          | ●         | ●        | ●        | ●           | ●           | ●        | ●         | ●        | ●        | ●        |
| 143 | 2002 | 6   | Unkn. | Unkn. | Biopsy | Unkn. | ●    | 17%      | ●        | ●          | ●         | ●        | ●        | ●           | ●           | ●        | ●         | ●        | ●        | ●        |
| 195 | 2006 | 34  | 25-80 | 50% | Biopsy | aE11  | ●    | ++       | ●        | ●          | ●         | ●        | ●        | ●           | ●           | ●        | ●         | ●        | ●        | ●        |
| 196 | 2008 | 34  | >15 | 50% | Biopsy | aE11  | ●    | ●        | ●        | ●          | ●         | ●        | ●        | ●           | ●           | ●        | ●         | ●        | ●        | ●        |
| 161 | 1997 | 7   | 51-75 | 71% | Biopsy | Unkn. | ●    | 100% ++  | ●        | ●          | ●         | ●        | ●        | ●           | ●           | ●        | ●         | ●        | ●        | ●        |
| 117 | 2010 | 12  | 21-70 | 50% | Biopsy | Unkn. | ●    | +++      | ●        | 100%       | ●         | ●        | ●        | ●           | ●           | ●        | ●         | ●        | ●        | ●        |
| 22  | 2013 | 29  | 28-89<sup>c</sup> | 41% | Biopsy | Unkn. | ●    | ●        | ●        | ●          | ●         | ●        | ●        | ●           | ●           | ●        | ●         | ●        | ●        | ●        |
| 53  | 2015 | 25  | 35-95<sup>cd</sup> | 63%<sup>d</sup> | Biopsy | Ab55811 | ●    | 60% +/+  | ●        | ●          | ●         | ●        | ●        | ●           | ●           | ●        | ●         | ●        | ●        | ●        |
| 130 | 2015 | 1   | 35  | 100% | Biopsy | A239  | ●    | ●        | ●        | ●          | ●         | ●        | ●        | ●           | ●           | ●        | ●         | ●        | ●        | ●        |
| 194 | 2017 | 49  | 32-90<sup>cd</sup> | 70%<sup>d</sup> | Biopsy | Unkn. | ●    | 78% +    | ●        | ●          | ●         | ●        | ●        | ●           | ●           | ●        | ●         | ●        | ●        | ●        |

**Interstitial nephritis**

|   | Year | Age | %  | Test | Diagnosis | HLA | ANCA | Anti-GBM | Anti-GPI | Anti-PLA2R | Anti-ASMA | Anti-SSA | Anti-SSB | Anti-Ro/SSA | Anti-La/SSB | Anti-MOG | Anti-NKCA | Anti-TO20 | Anti-TO22 | Anti-TO21 |
|---|------|-----|----|------|-----------|-----|------|----------|----------|------------|-----------|----------|----------|-------------|-------------|----------|-----------|----------|----------|----------|
| 96 | 1986 | Adult | Unkn. | Biopsy | aC5b-9(m) | ●    | 100% | +         | ○ 0%      | ●          | ●         | ●        | ●           | ●           | ●        | ●         | ●        | ●        | ●        |
| 70 | 1989 | 2   | Unkn. | Unkn. | Biopsy | C6 and C9 | ●    | +++      | ●          | +++        | ●         | ●        | ●           | ●           | ●        | ●         | ●        | ●        | ●        |
| 139 | 1997 | 46  | 3-70 | 61% | Biopsy | Unkn. | ●    | ●        | ●          | ●          | ●         | ●        | ●           | ●           | ●        | ●         | ●        | ●        | ●        |
| 143 | 2002 | 3   | Unkn. | Unkn. | Biopsy | Unkn. | ●    | 33%      | ●          | ●          | ●         | ●        | ●           | ●           | ●        | ●         | ●        | ●        | ●        |
| 118 | 2011 | 16  | Unkn. | Unkn. | Biopsy | Unkn. | ●    | ●        | ●          | ●          | ●         | ●        | ●           | ●           | ●        | ●         | ●        | ●        | ●        |
| 199 | 2011 | 1   | 59  | 100% | Biopsy | Unkn. | ●    | ●        | ●          | ●          | ●         | ●        | ●           | ●           | ●        | ●         | ●        | ●        | ●        |
| 31  | 2019 | 54  | 18-76<sup>c</sup> | 43% | Biopsy | aE11  | ●    | ●        | ●          | ●          | ●         | ●        | ●           | ●           | ●        | ●         | ●        | ●        | ●        |
Acute tubular necrosis

| No. | Year  | Age  | Gender | Tissue | Type   | C9/MA |
|-----|-------|------|--------|--------|--------|-------|
| 203 | 1993  | 1    | 21     | Biopsy | PolyC9-MA | ○     |
| 135 | 1993  | 31   | Unkn.  | Biopsy | Unkn.  |    |
| 94  | 1995  | 45   | Unkn.  | Biopsy | Unkn.  |    |
| 142 | 1999  | 21   | Unkn.  | Biopsy | Unkn.  |    |
| 200 | 2005  | 4    | 20-80d | Biopsy | C8     |    |
| 136 | 2018  | 21   | 35-93d | Autopsy| Unkn.  |    |
| 31  | 2019  | 5    | 25-65  | Biopsy | aE11   |    |
| 125 | 2020  | 6    | 51-86  | Autopsy| aE11   | 33%  |

Reflux nephropathy

| No. | Year  | Age  | Gender | Tissue | Type   | C9/MA |
|-----|-------|------|--------|--------|--------|-------|
| 44  | 1983  | 3    | Unkn.  | Biopsy or nephrect. | PolyC9-MA |    |
| 127 | 1987  | 8    | 8-51   | Biopsy or nephrect. | PolyC9-MA |    |
| 75  | 1993  | 1    | Unkn.  | Biopsy | PolyC9-MA |    |

Kidney tumors

| No. | Year  | Age  | Gender | Tissue | Type   | C9/MA |
|-----|-------|------|--------|--------|--------|-------|
| 210 | 1996  | 22   | 39-82  | Biopsy | Unkn.  | 82%h  |
| 138 | 1996  | 10   | Unkn.  | Unkn.  | PolyC9-MA | 10%h  |
| 209 | 2000  | 31   | Unkn.  | Nephrect. | aE11 | 16%h  |
| 207 | 2020  | 20   | 37-81c | Nephrect. | aE11 |    |

Kidney transplantation

| No. | Year  | Age  | Gender | Tissue | Type   | C9/MA |
|-----|-------|------|--------|--------|--------|-------|
| 96  | 1986  | 2    | Adults | Biopsy | αC5b-9(m) | 100%  |
| 214 | 1986  | 13   | 10-43  | Biopsy | αC5b-9(m) | 40%f  |
| 67  | 1987  | 4    | Unkn.  | Biopsy | PolyC9-MA |    |
| 70  | 1989  | 14   | Unkn.  | Biopsy | C6 and C9 |    |
| 143 | 2002  | 4    | Unkn.  | Biopsy | Unkn.  | 25%   |
| 129 | 2003  | 37   | 20-77  | Biopsy | aE11   |    |
| 83  | 2004  | 10   | 21-44c | Biopsy | Unkn.  | 50%   |
| 104 | 2009  | 1    | 20     | Biopsy | aE11   |    |
| 212 | 2012  | 1    | 13     | Biopsy | Unkn.  |    |
| 211 | 2013  | 33   | 10-83c | Biopsy | aE11   |    |
|     | 1     | Unkn. | Biopsy | aE11   |    |
|    |      | 67% | Biopsy |     | 100% | f | 63% | Biopsy |     | 100% | f | 63% | Biopsy |     | 100% | f | 63% | Biopsy |     | 100% | f |
|----|------|-----|--------|-----|------|---|-----|--------|-----|------|---|-----|--------|-----|------|---|-----|--------|-----|------|---|-----|--------|-----|------|---|-----|--------|-----|------|---|
| 54 | 2018 | 3   | 47-58  |     |      |   |      | ab55811 |   |      |   |      | ab55811 |   |      |   |      | ab55811 |   |      |   |      |      |
| 7  | 2018 | 7   | 28-47  |     |      |   |      |      |      |   |      | ab55811 |   |      |   |      | ab55811 |   |      |   |      |      |
| 2  | 2018 | 2   | 24-27  |     |      |   |      | ab55811 |   |      |   |      | ab55811 |   |      |   |      | ab55811 |   |      |   |      |      |
| 134| 2019 | 54  | 21-69c |     |      |   |      | B7   |      |   |      |      |      |      |   |      | 0% |      |      |      |      |
| 213| 2019 | 15  | 27-76c |     |      |   |      | Unkn. |      |   |      |      |      |      |   |      | 24%|      |      |      |      |
| 15 | 2019 | 15  | 27-76c |     |      |   |      | Unkn. |      |   |      |      |      |      |   |      |      | 25% |      |      |      |

\(^a\) Ages are given as ranges in years.

\(^b\) The staining of C5b-9 is described as absent (○) or present (●), as the proportion of patients exhibiting staining (%), and as the mean or median staining intensity on a scale from − to +++ in the glomerulus as a whole (glom.), the mesangium (mes.), the glomerular capillary wall (cap.), the tubules (tub.), and the extraglomerular vascular wall (vas.). The proportion of patients exhibiting staining is not given for studies including only one patient. The staining intensity is not given for studies including only patients exhibiting no staining. Nothing is indicated if the data were not reported.

\(^c\) An estimated range is given based on a mean with standard deviation or median with interquartile range reported in the original study, calculated as the mean minus plus two standard deviations or as the median minus two times the lower interquartile range and plus two times the higher interquartile range.

\(^d\) This characteristic was reported in the original study for a larger population, in an unspecified part of which deposition of C5b-9 was studied.

\(^e\) This finding concerns cases with the disease of interest, like hypertension or diabetes, but without related kidney disease, as detailed in the case descriptions in Supplementary Table 1. These cases were omitted from the calculations underlying Figure 1.

\(^f\) This finding concerns cases with secondary membranous nephropathy, IgA vasculitis with nephritis, postinfectious glomerulonephritis, or de novo membranous nephropathy after kidney transplantation and was omitted from the calculations underlying Figure 1, as indicated in the figure’s legend.

\(^g\) Age ranges and proportions of males are given for the transplant recipients.

\(^h\) This finding concerns staining localized in kidney tumor tissue, which is not classifiable as localized in the glomerulus, tubules, or vascular wall.

\(\alpha: \) anti; C3G: C3 glomerulopathy; C3GN: C3 glomerulonephritis; DDD: dense deposit disease; hypt.: hypertension; IC: immune complex-mediated; idio.: idiopathic; neph.: nephropathy; nephrect.: nephrectomy; pinf.: postinfectious; prim.: primary; ref: reference; sec.: secondary; STEC: Shiga toxin-producing enterohemorrhagic Escherichia coli; unkn.: unknown; vas.: vasculitis. Other abbreviations are explained in the article. Antibodies’ names correspond with those specified in Table 2.
**SUPPLEMENTARY TABLE 3** | Deposits of C5b-9 in healthy and diseased human kidneys as detected with different antibody

| Ref. | Year | N  | Ages\(^c\) | Males | Tissue | Kidney disease | Staining of C5b-9\(^b\) |
|------|------|----|------------|-------|--------|----------------|----------------------|
| Ab55811 | | | | | | | |
| 53  | 2015 | 25 | 35-95\(^d\) | 63\(^d\) | Biopsy | ANCA-vasculitis | ● 60% +/- |
| 54  | 2018 | 3  | 47-58 | 67% | Biopsy | Delayed graft function | ● 100% |
| 7   | 2018 | 28-47 | 57% | Biopsy | Acute rejection | ● 86% |
| 2   | 2018 | 24-27 | 100% | Biopsy | Chronic rejection | ● 100% |
| aE11 or M0777 | | | | | | | |
| 46  | 1985 | Unkn. | Unkn. | Autopsy | Healthy | ○ | ● |
| 110 | 1995 | 4  | Unkn. | Unkn. | Nephrect. | Healthy | ○ | ○ |
| 128 | 2001 | 5  | Unkn. | Unkn. | Nephrect. | Healthy | ● | |
| 112 | 2002 | 5  | Unkn. | Unkn. | Biopsy | Healthy | ○ 0% | ○ 0% | ○ 0% | ○ 0% |
| 129 | 2003 | 15 | 21-72\(^d\) | Unkn. | Biopsy | Healthy | ● | ○ | ● |
| 115 | 2008 | Unkn. | Unkn. | Unkn. | Nephrect. | Healthy | ○ | ○ | ○ |
| 103 | 2012 | 6  | Unkn. | Unkn. | Biopsy | Healthy | ● +/- | +/+ | ● ++ | ● +++ |
| 124 | 2017 | 15 | 8-56\(^c\) | 47% | Biopsy | Healthy | ○ 0% | | |
| 132 | 2018 | 12 | 23-83 | Unkn. | Autopsy or biopsy | Healthy | ● | ○ | |
| 28  | 2018 | 11 | 37-73\(^c\) | 45% | Nephrect. | Healthy | ● | ● | ● |
| 31  | 2019 | Unkn. | Unkn. | Nephrect. | Healthy | ○ | |
| 18  | 2019 | 6  | Unkn. | Unkn. | Unkn. | Healthy | ● 17% ± | ○ 0% | ● 17% +/- | ● |
| 102 | 2019 | 1  | Unkn. | Unkn. | Biopsy | Healthy | ● | | |
| 125 | 2020 | Unkn. | Unkn. | Unkn. | Healthy | ○ | ○ | ○ |
| 128 | 2001 | 5  | 15-34 | 60% | Biopsy | Minimal change neph. | ● 100% + | |
| 18  | 2019 | 4  | Unkn. | Unkn. | Unkn. | Minimal change neph. | ● 100% + | ○ 0% | ● 100% ++ | ● |
| 18  | 2019 | 4  | Unkn. | Unkn. | Unkn. | Thin basement dis. | ● 100% ± | ● 25% − | ● 75% ± | ● |
| 28  | 2018 | 62 | 27-79\(^c\) | 66% | Biopsy | Diabetic neph. | ● | ● | ● |
| 112 | 2002 | 35 | 23-71 | 66% | Biopsy | Membranous neph. | ● 23% | ● 100% | ● 100% | ● 80% |
| 148 | 2004 | 20 | 44-57\(^c\) | 70% | Biopsy | Membranous neph. | ● 100% | | |
| 156 | 2010 | 24 | 28-75 | 67% | Biopsy | Membranous neph. | ● | | |
| 150 | 2011 | 8  | 39-77 | 38% | Biopsy | Membranous neph. | ● | | |
| 153 | 2014 | Unkn. | Unkn. | Unkn. | Unkn. | Membranous neph. | ● | | |
| 18  | 2019 | 5  | Unkn. | Unkn. | Unkn. | Membranous neph. | ○ 0% | ● 100% +/+ | ● 50% ± | ● |
| No. | Year | Age | Gender | Biopsy Type | Disease | Stage | Histological Features |
|-----|------|-----|--------|-------------|---------|-------|----------------------|
| 110 | 1995 | 20  | 60%    | Biopsy     | IgA neph. | 95%   | 90% 75%              |
| 58  | 1995 | 2   | Unkn.  | Biopsy     | IgA neph. |       |                     |
| 160 | 1998 | 45  | 47%    | Biopsy     | IgA neph. | 100%  |                     |
| 99  | 2000 | 10  | 40%    | Biopsy     | IgA vasc. | 100%  |                     |
| 128 | 2001 | 14  | 43%    | Biopsy     | IgA neph. | 100% ++|                     |
| 115 | 2008 | 30  | 75%    | Biopsy     | IgA neph. | +/+ 100% | 100% 100% 100% 81% |
| 165 | 2017 | 96  | 65%    | Biopsy     | IgA neph. | 100%  |                     |
| 124 | 2017 | 25  | 80%    | Biopsy     | IgA neph. | 100% +|                     |
| 46  | 1985 | 1   | 18%    | Biopsy     | Lupus nephritis |       |                     |
| 172 | 2008 | 1   | 27%    | Biopsy     | Lupus nephritis V | 100% |                     |
| 18  | 2019 | 20  | 20%    | Biopsy     | Lupus nephritis III | 85% + 65% + 70% + |                     |
| 22  | 2019 | 21  | 13%    | Biopsy     | Lupus nephritis IV | 87% +/+ 59% +/+ 82% + |                     |
| 13  | 2019 | 18  | 23%    | Biopsy     | Lupus nephritis V | 46% - 100% +++ 69% - |                     |
| 103 | 2012 | 2   | 100%   | Biopsy     | C3GN      | 100% +/+/ 100% +++ 100% +++ 100% +++ |                     |
| 102 | 2012 | 24  | 52%    | Biopsy     | C3G       | 100% +/+ |                     |
| 8   | 2012 | 9-74 | 52%    | Biopsy     | C3G       | 100% + |                     |
| 103 | 2012 | 1   | Unkn.  | Biopsy     | aHUS      | ++++++ |                     |
| 153 | 2014 | 10  | 18%    | Biopsy     | STEC      |       |                     |
| 188 | 2015 | 1   | 16%    | Biopsy     | aHUS      |       |                     |
| 132 | 2018 | 5   | 60%    | Biopsy     | TTP       | 0% 40% 60% |                     |
| 8   | 2018 | 22-66 | 0%    | Biopsy or Autopsy | TTP | 0% 20% 40% |                     |
| 100 | 2019 | 6   | 50%    | Biopsy     | TMA       | 100% + 33% +/+ 100% +++ |                     |
| 7   | 2019 | 32-72 | 29%  | Biopsy     | TMA       | 100% +/+ 14% ++ |                     |
| 195 | 2006 | 34  | 50%    | Biopsy     | ANCA-vasculitis | ++ |                     |
| 196 | 2008 | 34  | >15%   | Biopsy     | ANCA-vasculitis | ++ |                     |
| 31  | 2019 | 54  | 43%    | Biopsy     | Interstitial nephritis |       |                     |
| 31  | 2019 | 5   | 25-65  | 60%    | Biopsy     | Acute tubular necrosis |       |                     |
| 125 | 2020 | 6   | 51-86  | 67%    | Autopsy   | Acute tubular necrosis | 33% 100% +/+ 33% |                     |
| 209 | 2000 | 31  | Unkn.  | Nephrect. | Renal cell carcinoma | h 16% h 4h |                     |
| 207 | 2020 | 20  | 57%    | Nephrect. | Renal cell carcinoma | o h |                     |
| 129 | 2003 | 37  | 57%    | Biopsy    | After transplantation |       |                     |
| 104 | 2009 | 1   | 100%   | Biopsy    | Transplant rejection |       |                     |
| 211 | 2013 | 33  | 61%    | Biopsy    | Reperfusion |       |                     |
| 1   | Unkn. | 1   | Unkn.  | Biopsy    | Transplant rejection |       |                     |
| Anti-C5b-9(m)                  | 96  | 1986 | 6 | Adults | Unkn. | Biopsy    | Healthy |       |       |       |
|-------------------------------|-----|------|---|--------|-------|-----------|---------|-------|-------|-------|
|                               | 2   | Adults | Unkn. | Biopsy | Healthy |           |         |       |       |       |
|                               | 72  | 1989 | 3 | Adults | Unkn. | Biopsy    | Healthy |       |       |       |
|                               | 96  | 1986 | 5 | Adults | Unkn. | Unkn.    | Minimal change neph. | 100% | + 0% |       |       |
|                               | 141 | 1986 | 3 | 2-14d | Unkn. | Biopsy    | Minimal change neph. |       |       |       |       |
|                               | 98  | 1987 | 3 | 2-14d | Unkn. | Biopsy    | Minimal change neph. |       |       |       |       |
|                               | 72  | 1989 | 3 | Adults | Unkn. | Unkn.    | Minimal change neph. |       |       |       |       |
|                               | 96  | 1986 | 1 | Adult  | Unkn. | Unkn.    | Alport's syndr. |       |       |       |       |
|                               | 96  | 1986 | 2 | Adults | Unkn. | Unkn.    | Diabetic neph. | 100% | ++ 0% |       |       |
|                               | 72  | 1989 | 3 | Adults | Unkn. | Unkn.    | Diabetic neph. |       |       |       |       |
|                               | 96  | 1986 | 6 | Adults | Unkn. | Unkn.    | Membranous neph. | 0%   | 100% | ++     |       |
|                               | 96  | 1986 | 7 | Adults | Unkn. | Unkn.    | Membranous neph. | 78%  | + 22% | +/++   |       |
|                               | 141 | 1986 | 2 | 2-14d | Unkn. | Biopsy    | Membranous neph. |       |       | 100% | ++     |
|                               | 98  | 1987 | 2 | 2-14d | Unkn. | Biopsy    | Membranous neph. |       |       |       |       |
|                               | 72  | 1989 | 7 | Adults | Unkn. | Unkn.    | Membranous neph. |       |       |       |       |
|                               | 96  | 1986 | 7 | Adults | Unkn. | Unkn.    | IgA neph. | 100% | ++/++ | 14%    | +     |
|                               | 2   | Adults | Unkn. | Unkn. | IgA vasc. |           | 100% | + 0% |       |       |
|                               | 72  | 1989 | 10| Adults | Unkn. | Unkn.    | IgA neph. |       |       |       |       |
|                               | 58  | 1995 | 2 | Unkn. | Unkn. | Biopsy    | IgA neph. |       |       |       |       |
|                               | 96  | 1986 | 1 | Adult  | Unkn. | Biopsy    | Lupus nephritis II |       |       |       |       |
|                               | 8   | Adults | Unkn. | Biopsy | Lupus nephritis IV | 100% | ++ 88% | ++     |       |
|                               | 72  | 1989 | 7 | Adults | Unkn. | Unkn.    | Lupus nephritis II-IV |       |       |       |       |
|                               | 58  | 1995 | 2 | Unkn. | Unkn. | Biopsy    | Lupus nephritis IV |       |       |       |       |
|                               | 96  | 1986 | 9 | Adults | Unkn. | Biopsy    | MPGN I | 89% | 100% | ++     |       |
|                               | 141 | 1986 | 2 | 2-14d | Unkn. | Biopsy    | MPGN | 0%   | 50%  | 50% |       |
|                               | 98  | 1987 | 2 | 2-14d | Unkn. | Biopsy    | MPGN | 50%  |       |       |       |
|                               | 72  | 1989 | 5 | Adults | Unkn. | Unkn.    | MPGN I |       |       |       |       |
|                               | 96  | 1986 | 1 | Adult  | Unkn. | Biopsy    | Interstitial nephritis | 100% | + 0% |       |       |
|                               | 96  | 1986 | 2 | Adults | Unkn. | Biopsy    | Transplant rejection | 100% | + 0% |       |       |
|                               | 214 | 1986 | 13| 10-43 | 38% | Biopsy    | De novo membranous neph. in transplant | 40% | 60% |       |       |
### Anti-MAC

| 57 | 1989 | 6 | Unkn. | Unkn. | Biopsy | Minimal change neph. | ● | ○ | ● | ● |
| 57 | 1989 | 22 | Unkn. | Unkn. | Biopsy | Membranous neph. | ● | ++ | ● | ● |
| 57 | 1989 | 75 | Unkn. | Unkn. | Biopsy | IgA neph. | ● | +++ | ● | ● |
| 57 | 1989 | 20 | Unkn. | Unkn. | Biopsy | Lupus nephritis | ● | 79% | ● | ● |
| 57 | 1989 | 11 | Unkn. | Unkn. | Biopsy | MPGN I | ● | ● | ● | ● |
| 1 | Unkn. | Unkn. | Biopsy | MPGN II | ● | ● | ● | ● | ● |

### Anti-MAC-neo

| 52 | 1987 | 4 | 5-37 | 75% | Biopsy | Healthy | ○ | 0% | ○ | 0% |
| 52 | 1987 | 23 | 6-56 | 78% | Biopsy | IgA neph. | ● | 100% | ++ | 56% | + | 76% | ● | 76% |
| 2 | 9-10 | 50% | Biopsy | IgA vasc. | ● | 100% | +++ | 100% | +/-|

### bC5 or A239

| 130 | 2015 | 9 | Unkn. | Unkn. | Unkn. | Healthy | ● | 78% |
| 79 | 1994 | 2 | 18-23 | 50% | Biopsy | Minimal change neph. | ● | + | ○ | ● | +++ |
| 130 | 2015 | 5 | Unkn. | Unkn. | Biopsy | Alport's syndr. | ○ | 0% | ● | + | ○ | 0% |
| 79 | 1994 | 6 | 47-65 | 33% | Biopsy | Membranous neph. | ● | + | ● | +++ | ● | + |
| 130 | 2015 | 1 | 32 | 100% | Biopsy | IgA neph. | ○ | ● | ● | ○ | ● |
| 167 | 2019 | 116 | 0-84 | 69% | Biopsy | IgA neph. or vasc. | ● | 15% | ● | 50% |
| 130 | 2015 | 8 | 17-49 | 0% | Autopsy or biopsy | TMA | ● | 60% | ● | 60% |
| 130 | 2015 | 11 | 22-77 | 18% | Autopsy or biopsy | aHUS | ● | ● | ● |
| 1 | 14 | 100% | Biopsy | STEC | ○ | ● | ● |
| 6 | 18-54 | 50% | Autopsy or biopsy | TMA | ● | ○ | ● |
| 3 | 6-37 | 67% | Biopsy or nephrect. | aHUS | ● | ● | ● |
| 130 | 2015 | 1 | 35 | 100% | Biopsy | ANCA-vasculitis | ● | ● | ● |

### B7

| 134 | 2019 | 1 | Unkn. | Unkn. | Biopsy | Healthy | ○ | ○ | ● |
| 58 | 1995 | 2 | Unkn. | Unkn. | Biopsy | IgA neph. | ● | ● |
| 58 | 1995 | 2 | Unkn. | Unkn. | Biopsy | Lupus nephritis IV | ● | ● |
| 134 | 2019 | 54 | 21-69 | 63% | Biopsy | Transplant rejection | ○ | 0% | 24% | + | ● | ● | 2% | ++ |
| Kolb 1975 | | | | | |
|---|---|---|---|---|---|
| 95 | 1981 | 3 | Unkn. | Unkn. | Unkn. | Healthy | ○ | |
| 95 | 1981 | 2 | Unkn. | Unkn. | Unkn. | Hypertensive neph. | ○ | ○ |
| 95 | 1981 | 2 | Unkn. | Unkn. | Unkn. | Lupus nephritis II | ● 100% | ● 100% | ● 100% | + | ● |
| 7 | Unkn. | Unkn. | Autopsy or biopsy | Lupus nephritis III | ● 86% | + | ● 86% | + | ● 100% | +/+ |
| 10 | Unkn. | Unkn. | Autopsy or biopsy | Lupus nephritis IV | ● 100% | ++ | ● 100% | ++ | ● 100% | ++ |
| 3 | Unkn. | Unkn. | Autopsy or biopsy | Lupus nephritis V | ○ 0% | ● 67% | ++ | ● 100% | ++ |

| PolyC9-MA | | | | | |
|---|---|---|---|---|---|
| 44 | 1983 | Unkn. | Fetus | Unkn. | Healthy | ○ | ○ | ○ | ○ | |
| 44 | 1983 | Unkn. | Adult | Unkn. | Healthy | ● | ○ | ○ | ● | ● |
| 67 | 1987 | 6 | Unkn. | Unkn. | Biopsy | Healthy | ● | ± | ○ | ● | + | ● | +/+ |
| 126 | 1987 | 1 | 0 | Unkn. | Autopsy or unkn. | Healthy | ● | ○ | ○ | ● | ● |
| 127 | 1987 | 4 | Unkn. | Unkn. | Unkn. | Healthy | ● | ○ | ○ | ● | ● |
| 137 | 1987 | 2 | Unkn. | Unkn. | Nephrect. | Healthy | ○ 0% | ● 100% | +++ |
| 97 | 1988 | 4 | 43-66 | Unkn. | Unkn. | Healthy | ● | ○ | ● | ● |
| 75 | 1993 | Unkn. | Unkn. | Nephrect. | Healthy | ● | ○ | ● | ● |
| 138 | 1996 | 10 | Unkn. | Unkn. | Unkn. | Healthy | ● | ○ | ● | ● |
| 67 | 1987 | 7 | Unkn. | Unkn. | Biopsy | Minimal change neph. | ● | ± | ○ | ● | + | ● | +/+ |
| 81 | 1991 | 9 | Unkn. | Unkn. | Biopsy | Minimal change neph. | ● | ○ | ● | ○ | ● |
| 75 | 1993 | 10 | Unkn. | Unkn. | Biopsy | Minimal change neph. | ● | ○ | ● | ● |
| 44 | 1983 | 3 | Unkn. | Unkn. | Biopsy or nephrect. | Hypertensive neph. | ● | ○ | ● | ● |
| 67 | 1987 | 6 | Unkn. | Unkn. | Biopsy | Hypertensive neph. | ● | + | ○ | ● | +/+ | ● | +++ |
| 44 | 1983 | 7 | Unkn. | Unkn. | Biopsy or nephrect. | Diabetic neph. | ● | ○ | ● | ● | ● |
| 67 | 1987 | 9 | Unkn. | Unkn. | Biopsy | Diabetic neph. | ● | + | ○ | ● | ++ | ● | ++ |
| 126 | 1987 | 12 | Unkn. | Unkn. | Biopsy or nephrect. | Diabetic neph. | ● | ● 25% | ● | ● |
| 44 | 1983 | 3 | Unkn. | Unkn. | Biopsy | Membranous neph. | ○ | ● | ● |
| Case | Year | Age | Gender | Diagnosis | Histology | Severity 1 | Severity 2 | Severity 3 | Severity 4 |
|------|------|-----|--------|-----------|-----------|------------|------------|------------|------------|
| 67   | 1987 | 11  | Unkn.  | Biopsy    | Membranous neph. | ++ | ++ | ++ | +++ |
| 152  | 1989 | 2   | 5-15   | 100% Biopsy | Membranous neph. | 100% | 100% | 100% | 100% |
| 6    | 19  | 3-13 | Biopsy Membranous neph. | 83% | 83% | 83% | 83% |
| 81   | 1991 | 15  | Unkn.  | Biopsy Membranous neph. | 100% | 100% | 100% | 100% |
| 75   | 1993 | 2   | Unkn.  | Biopsy Membranous neph. | 73% | 73% | 73% | 73% |
| 44   | 1983 | 3   | Unkn.  | Biopsy IgA neph. | 93% | 93% | 93% | 93% |
| 137  | 1987 | 12  | Unkn.  | Biopsy IgA neph. | 100% | 100% | 100% | 100% |
| 67   | 1987 | 11  | Unkn.  | Biopsy IgA neph. | 93% | 93% | 93% | 93% |
| 97   | 1988 | 30  | 4-17   | 70% Biopsy | IgA neph. | 93% | 93% | 93% | 93% |
| 81   | 1991 | 1   | 23 Unkn. Biopsy | 100% | 100% | 100% | 100% |
| 75   | 1993 | 2  | Unkn.  | Biopsy IgA neph. | 100% | 100% | 100% | 100% |
| 44   | 1983 | 3   | Unkn.  | Biopsy IgA vasc. | 100% | 100% | 100% | 100% |
| 44   | 1983 | 3   | Unkn.  | Biopsy Lupus nephritis | 100% | 100% | 100% | 100% |
| 67   | 1987 | 8   | Unkn.  | Biopsy Lupus nephritis III, IV | 86% | 86% | 86% | 86% |
| 44   | 1983 | 3   | Unkn.  | Biopsy MPGN I | 86% | 86% | 86% | 86% |
| 183  | 1984 | 11  | 5-14   | 45% Biopsy | Postinfectious | 100% | 100% | 100% | 100% |
| 67   | 1987 | 3   | Unkn.  | Biopsy MPGN I | 93% | 93% | 93% | 93% |
| 126  | 1987 | 3   | Unkn.  | Biopsy MPGN II | 100% | 100% | 100% | 100% |
| 75   | 1993 | 4   | Unkn.  | Biopsy Lupus nephritis IV | 100% | 100% | 100% | 100% |
| 75   | 1993 | 3   | Unkn.  | Biopsy MPGN III | 100% | 100% | 100% | 100% |
| 203  | 1993 | 1   | 21 100% Biopsy | Acute tubular necrosis | 100% | 100% | 100% | 100% |
| 44   | 1983 | 3   | Unkn.  | Biopsy or nephrect. | 100% | 100% | 100% | 100% |
| 127  | 1987 | 8   | 8-51   | 13% Biopsy or nephrect. | 100% | 100% | 100% | 100% |
| 75   | 1993 | 4   | Unkn.  | Biopsy Reflux neph. | 100% | 100% | 100% | 100% |
| 138  | 1996 | 10  | Unkn.  | Unkn. Conn. | Renal cell carcinoma | 60% | 60% | 60% | 60% |
| 67   | 1987 | 8   | 8-51   | 13% Biopsy or nephrect. | 100% | 100% | 100% | 100% |
| Patient ID | Year  | Age | Gender | Diagnosis  | Biopsy   | Morphology  | Disease Activity | Follow-up | Comments |
|------------|-------|-----|--------|------------|----------|-------------|-----------------|-----------|----------|
| WU-7,2     | 1996  | 7   | Unkn.  | Nephrect.  | Healthy  | 43% +       | 0%              | 0%        |          |
|            | 1996  | 5   | Unkn.  | Biopsy    | Lupus nephritis II | +/++ | 100% | 0%        |          |
|            | 3     | Unkn. | Biopsy | Lupus nephritis II | +++ | 100% | 0%        |          |
|            | 7     | Unkn. | Biopsy | Lupus nephritis IV | +++ | 100% | 100%        |          |
| WU-13,15   | 2013  | 11  | 23-41  | Biopsy    | Lupus nephritis II-V | 100% | +++ |           |          |
|            | 2     | 23-41 | 27%    | Biopsy    | Lupus nephritis II | 100% | +++ |           |          |
|            | 3     | 23-41 | 27%    | Biopsy    | Lupus nephritis III | 100% | +/+ |           |          |
|            | 3     | 23-41 | 27%    | Biopsy    | Lupus nephritis IV | 100% | +++ |           |          |
|            | 3     | 23-41 | 27%    | Biopsy    | Lupus nephritis V  | 100% | +/+ |           |          |
|            | 190   | 1    | 26     | Biopsy    | STEC      |          |               |           |          |
| X197       | 2018  | 30  | 8-59   | Biopsy    | Lupus nephritis II-V | 100% | +++ |           |          |
|            | 2     | 8-59  | 20%    | Biopsy    | Lupus nephritis II | 0% |     |           |          |
|            | 5     | 8-59  | 20%    | Biopsy    | Lupus nephritis III | 20% |     |           |          |
|            | 8     | 8-59  | 20%    | Biopsy    | Lupus nephritis IV | 50% |     |           |          |
|            | 5     | 8-59  | 20%    | Biopsy    | Lupus nephritis V  | 60% |     |           |          |
|            | 8     | 8-59  | 20%    | Biopsy    | Lupus nephritis III+V | 50% |     |           |          |
|            | 2     | 8-59  | 20%    | Biopsy    | Lupus nephritis IV+V | 50% |     |           |          |
| Xia 1988   | 1990  | 3   | Unkn.  | Biopsy    | Minimal change neph. | 0% |     |           |          |
|            | 1990  | 4   | Unkn.  | Biopsy    | IgA vasc.  | 100% | +/+ |           |          |
| 1B4        | 2006  | 7   | Children | Unkn. | Unkn. | Healthy | 0% | 0%        |          |
|            | 2006  | 18  | Children | 56% | Biopsy | MPGN I | 94% | +/+ |           |          |

For a legend, see the legend of Supplementary Table 2.
SUPPLEMENTARY FIGURE 1 | Deposits of C5b-9 in healthy human kidneys as detected with different antibodies. Pie charts show the proportion of studies that reported staining of C5b-9 as absent (light) or present (dark). Bar charts show the medians of the proportions of patients reported to exhibit staining. Scatter charts show the median staining intensities in these patients. All charts show data separately for staining in the glomerulus as a whole (glom.), in the mesangium (mes.), along the glomerular capillary wall (cap.), along the tubular basement membrane (tub.), or in the extraglomerular vascular wall (vas.). Error bars show the lowest and highest reported values. Numbers of studies are indicated between brackets. Some studies reported only part of the data shown, explaining differences in the numbers of studies between pie, bar, and scatter charts. Nothing is indicated if the data were never reported. Detailed data per study are listed in Supplementary Table 3. Data on antibodies used in only one original study are only listed in Supplementary Table 2. Antibodies’ names correspond with those specified in Table 2.
SUPPLEMENTARY FIGURE 2 | Deposits of C5b-9 in diseased human kidneys as detected with different antibodies. Pie charts show the proportion of studies that reported staining of C5b-9 as absent (light) or present (dark). Bar charts show the medians of the proportions of patients reported to exhibit staining. Scatter charts show the median staining intensities in these patients. All charts show data separately for staining in the glomerulus as a whole (glom.), in the mesangium (mes.), along the glomerular capillary wall (cap.), along the tubular basement membrane (tub.), or in the extraglomerular vascular wall (vas.). Error bars show the lowest and highest reported values. Numbers of studies are indicated between brackets. Some studies reported only part of the data shown, explaining differences in the numbers of studies between pie, bar, and scatter charts. Nothing is indicated if the data were never reported. Detailed data per study are listed in Supplementary Table 3. Data on antibodies used in only one original study are only listed in Supplementary Table 2. Antibodies’ names correspond with those specified in Table 2. Note that the data reflect various kidney diseases.
SUPPLEMENTARY FIGURE 3 | Deposits of C5b-9 in healthy human kidneys as detected with different staining techniques. Pie charts show the proportion of studies that reported staining of C5b-9 as absent (light) or present (dark). Bar charts show the medians of the proportions of patients reported to exhibit staining. Scatter charts show the median staining intensities in these patients. All charts show data separately for staining in the glomerulus as a whole (glom.), in the mesangium (mes.), along the glomerular capillary wall (cap.), along the tubular basement membrane (tub.), or in the extraglomerular vascular wall (vas.). Error bars show the lowest and highest reported values. Numbers of studies are indicated between brackets. Some studies reported only part of the data shown, explaining differences in the numbers of studies between pie, bar, and scatter charts. Nothing is indicated if the data were never reported. Detailed data per study are listed in Supplementary Table 2.
**SUPPLEMENTARY FIGURE 4 | Deposits of C5b-9 in diseased human kidneys as detected with different staining techniques.** Pie charts show the proportion of studies that reported staining of C5b-9 as absent (light) or present (dark). Bar charts show the medians of the proportions of patients reported to exhibit staining. Scatter charts show the median staining intensities in these patients. All charts show data separately for staining in the glomerulus as a whole (glom.), in the mesangium (mes.), along the glomerular capillary wall (cap.), along the tubular basement membrane (tub.), or in the extraglomerular vascular wall (vas.). Error bars show the lowest and highest reported values. Numbers of studies are indicated between brackets. Some studies reported only part of the data shown, explaining differences in the numbers of studies between pie, bar, and scatter charts. Nothing is indicated if the data were never reported. Detailed data per study are listed in Supplementary Table 2. Note that the data reflect various kidney diseases.
SUPPLEMENTARY FIGURE 5 | Deposits of C5b-9 in healthy human kidneys as detected in different tissue sources. Pie charts show the proportion of studies that reported staining of C5b-9 as absent (light) or present (dark). Bar charts show the medians of the proportions of patients reported to exhibit staining. Scatter charts show the median staining intensities in these patients. All charts show data separately for staining in the glomerulus as a whole (glom.), in the mesangium (mes.), along the glomerular capillary wall (cap.), along the tubular basement membrane (tub.), or in the extraglomerular vascular wall (vas.). Error bars show the lowest and highest reported values. Numbers of studies are indicated between brackets. Some studies reported only part of the data shown, explaining differences in the numbers of studies between pie, bar, and scatter charts. Nothing is indicated if the data were never reported. Detailed data per study are listed in Supplementary Tables 2 and 3.
SUPPLEMENTARY FIGURE 6 | Deposits of C5b-9 in diseased human kidneys as detected in different tissue sources. Pie charts show the proportion of studies that reported staining of C5b-9 as absent (light) or present (dark). Bar charts show the medians of the proportions of patients reported to exhibit staining. Scatter charts show the median staining intensities in these patients. All charts show data separately for staining in the glomerulus as a whole (glom.), in the mesangium (mes.), along the glomerular capillary wall (cap.), along the tubular basement membrane (tub.), or in the extraglomerular vascular wall (vas.). Error bars show the lowest and highest reported values. Numbers of studies are indicated between brackets. Some studies reported only part of the data shown, explaining differences in the numbers of studies between pie, bar, and scatter charts. Nothing is indicated if the data were never reported. Detailed data per study are listed in Supplementary Tables 2 and 3. Note that the data reflect various kidney diseases.